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PREFACE 
 
Our interest in skin regeneration arises from the evidence that chronic ulcers, and especially those 
in diabetic patients, are difficult to cure and are widespread in all countries. The incidence of this 
disease is particularly high in our region (Liguria, Italy), affecting mainly elderly population that 
need of home care for the treatment of chronic ulcers. 
Skin ulcers are sore localized on the skin or on a mucous membrane, accompanied by the 
disintegration of tissue that occurs predominantly in bedridden patients. The ulcers are due to a re-
epithelization process not physiologic determined by several factors during the regeneration of the 
skin. One of the pathologies that can lead to the development of skin ulcers is diabetes, which 
incidence in recent years, has strongly increased. One of most important problems related to the 
diabetic skin ulcers is the chronicity of the lesion that leads to a constant and prolonged demand for 
care by the patient, becoming a big social issue.  
To date, the "conventional" treatment for the healing of crucial ulcers is the debridement, that 
results in the reduction of the infection at the site. This approach induces a stimulation of the 
reepithelization process, that in most cases is intercepted by the presence of necrotic tissue. 
Subsequently, the wound bed is threated with different techniques such as physical stimulation 
(hyperbaric oxygen therapy, negative pressure therapy, and ultrasound treatment) [1,2] and 
advanced methods including growth factor therapy. The average duration of an ulcer is 
approximately 26 weeks, with a range that vary from 4 weeks to 30 years in the worst cases. 
However, in 46% of patients the clinical course exceeds 26 weeks and in 15% of patients is over 
two years. 
The care of these critical lesions represents one of the main aim of the regenerative medicine. 
In this regard, recently, it has been introduced the treatment of the skin ulcers with Platelet Rich 
Plasma (PRP) gel. The PRP gel is a matrix consisting mainly of platelets, that are activated by 
thrombin to release growth factors important in the starting and sustaining of the process of tissue 
regeneration. 
In this field I carried out my PhD course project in Regenerative Medicine with Curriculum 
Translational Medicine during which I studied the role of growth factors derived from the platelets 
in term of their effect on the cell proliferation and their use in the treatment and care of skins ulcers. 
The Thesis, here presented, is organized in three chapters: 
1) Platelet derivatives effect on the proliferative stage of mesenchymal stem cells and cell lines, and 
MYC pathway activation; 
2) Electrospun silk fibroin fibers for storage and controlled release of human platelet lysate; 
3) Sericin, alginate and platelet lysate combined in a biomembrane for the treatment of skin ulcers. 
In support of the original design of the thesis project, there were publications that our team had 
previously published on the role of PRP as a potential substitute of the fetal calf serum in cell 
cultures and as its potential use for tissue regeneration.  
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Zaky et al. and Muraglia et al. [3,4] have described in different papers a platelet derivative able to 
stimulate cell proliferation, allowing cells to maintain their phenotypical characteristics and 
differentiation capacity. In 2016 were published the first results regarding the efficiency of a PRP 
bioactive membrane fabricated according to the standard protocols used in the Blood Transfusion 
Centre. The novelty of this membrane respect to others is the standardization of growth factors 
content based indirectly on the number of platelets/microliter associated to the membrane. This 
allowed the generation of different typologies of membranes adaptable to different applications in 
relation to the severity of the lesions.  
Based on this background, the aim of the Thesis was the study of the effects of platelet growth 
factors on the cells to understand the molecular activated mechanisms responsible for the increased 
proliferation. In parallel with the aim to identify a cutaneous patch based on PRP, we studied a new 
membrane based on the combination of platelet derivatives and silk proteins that are considered 
good scaffolds in the tissue regeneration. Here either fibroin or sericin were used in combination 
with platelet derivatives to generate a membrane able to release, in a controlled fashion, platelet 
growth factors to simulate the microenvironment for the repair of the skin wound. To achieve this 
goal, we established collaborations with two different research groups. 
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OUTLINE 
 
To date, the major part of culture medium supplements is based on animal sera. The use cell culture 
is increasing, and innovative supplements to expand cells are constantly developed.  
As it is well known, there are several problems related to the use of animal sera.  These problems 
are not only scientific, ethical and technical, dealing with the conservation, starvation and lot to lot 
variation [5–7], but also regarding the limited use of the Fetal Calf Serum (FCS) for the expansion 
of cells intended for clinical applications [4]. In June 2011, the European Commission released 
guidelines to minimize the risk of transmitting animal spongiform encephalopathy agents via 
human and veterinary medicinal products (EMA/410/01 Revision 3). These guidelines suggested 
the preferential use of supplements of non-animal origin for the cultivation of cell cultures [4]. For 
this reasons, the human derivatives, in particular the platelets derivatives, have earned a huge 
success based on the presence of a mix of growth factors that promote cell proliferation and 
differentiation, one of most important step in the regenerative process.  
In literature there are several publications related to the use of platelet derivatives as supplement for 
culture medium: however, these publications, report controversial results. This can be explained by 
the different procedures that are applied for the supplement preparation resulting in different 
contents of platelets and growth factors released [8]. 
In 2015, the research group in which I worked during the PhD training, published an article that 
showed for the first time a dual component based on platelet and plasma derivatives to be used in 
replacing FCS in cell culture system. The main characteristics of this platelet derivative were the 
derivation from discarded pool of human healthy donor blood donations, and the standardization in 
term of  their content of growth factors to reduce the variability in the different preparations [4]. 
Starting from these observations, I designed the first part of my PhD program to understand the 
effect of platelet derivatives on cell proliferation, investigating its efficiency respect to FCS, the 
standard used supplement, and the activated molecular pathways at the base of its proliferation 
stimulation efficiency.  
Traditional treatments of degenerative pathologies include, physical stimulation (hyperbaric oxygen 
therapy, negative pressure therapy, and ultrasound treatment) [1,2] and advanced methods such as 
growth factor therapy [2,9]. Furthermore, these treatments are, in most cases, merely palliative. The 
well-known capability of platelet derivatives in promoting cell proliferation, suggested their use in 
the clinical practice, in most cases in the form of autologous Platelet Rich Plasma (PRP) [9-12]. 
In orthopaedic, PRP has been used for the treatment of bone, tendon and ligament disorders, while 
in the dentistry it has been employed to promote tissue growth and to speed up the healing process. 
Recently, many experimental attempts to favour faster healing of the wound, have been done with a 
tissue engineering approach in order to develop medical bioactive devices (patches, membranes 
etc.) [14]. 
At the beginning of my PhD, I participated in a work which had the objective to characterize a 
biomembrane based on allogenic PRP with a standardized platelet concentration for the treatment of 
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skin chronic ulcers. This work yielded  a manuscript entitled Platelet Rich Plasma-based Bioactive 
Membrane as a New Advanced Wound Care Tool [15], where two different bioactive membranes 
(BAM) based on a different platelet concentration [2.0E6 (Low-BAM) and 10E6 (High-BAM) 
platelets/mL] were compared and characterized for their ability to release growth factors and their 
regenerative potential in an animal model. The BAM were prepared by a standardized method, 
starting from human derived components, to ensure the biocompatibility and a complete 
biodegradation and resorption [16]. The growth factors release and the speed of biodegradation of 
the BAM were controlled by varying the platelet concentration inside the PRP, in the presence of 
cryoprecipitate. The control of the gel biodegradability and of the growth factor release is very 
important issues. BAM maintain a wet environment in the wound area that is favourable for the best 
tissue regeneration [17]. This feature, in combination with the strong pro-inflammatory induction 
determined by the platelet release, should restore the correct micro-environment in the wounded 
area, thus enhancing wound healing and closure [18]. In the skin chronic wound animal mouse 
model, the L-BAM performed better than H-BAM. However, it remains to be investigated if, unlike 
in the mouse model, in the human chronic wounds, where the skin layers are thicker than in rodents, 
both BAM could be of benefit in enhancing wound closure. In particular, H-BAM could be used for 
the treatment of deeper skin lesions, where it is necessary a stronger tissue granulation formation, 
while the L-BAM could be used for the treatment of more superficial skin lesions. 
The conclusions lead to consider the PRP-BAM a new powerful tool for the treatment of chronic 
and difficult to heal skin ulcers.  
The skin lesions, in particular the ulcers, represent especially for a diabetic patient, one of most 
common cause of, infections, ischemia and lower limb amputations in the United States and 
Europe. Despite the introduction of endovascular revascularization techniques, wound therapeutics, 
and advances in the medical management of diabetes, the number of patients that need limb 
amputation have not decrease in the last years. 
 
The physiologic wound healing process consists of four phases that overlap at some points and are 
summarized in Figure 1: 
• Coagulation and haemostasis, 
• Inflammation, 
• New tissue formation, 
• Remodelling. 
 
The first wound healing phase occurs immediately after tissue damage with the coagulation and 
haemostatic process [19,20]. This mechanism starts to prevent exsanguination. This first phase 
occurs to provide a matrix for invading cells that are needed in the late phase [21]. The amount of 
fibrin deposit at the wound site is represented by a changing balance between different types of 
cells and process [22]. Simultaneously with haemostatic events begin the coagulation cascade that 
starts with the release of factors that activate the extrinsic and intrinsic pathway: platelets that occur 
firstly during this phase are recruited at the site of the wound where release growth factors 
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necessary for the recruitment of the cells of the immune system. At the same time platelet factors 
and thrombin co-ordinate the formation of a gel, the basis of the clot, mainly consisting of fibrin 
which will form the "scaffold" for cellular infiltration of the next stage. 
The second stage turns up within 24-72 hours. This phase is divided in two parts, an early 
inflammatory phase and a late inflammatory phase [23]. In the early inflammation neutrophils 
invade the wound site in order to remove the bacteria or other molecules present in the site [23]. 
Neutrophils in this phase become sticky and begin to adhere to the endothelial cells in the post-
capillary venules surrounding the wound [22-24]. Then, the neutrophils, move along the 
endothelium surface and begin to be pushed forward by the blood flow [25]. To complete the phase, 
the neutrophils must be eliminated from the wound, so the redundant cells are eliminated by 
extrusion or apoptosis, without creating damage to the wound or  potentiating the inflammatory 
response [23,26]. The debris that remain in the wound site are later phagocytized from the 
macrophages. This part of the wound healing process represents the late inflammatory phase, while 
continuing the phagocytosis mechanism. The macrophages that participate in this phase are 
important cells that act as key regulatory cells providing abundant growth factors, that activate other 
cells like keratinocytes, fibroblasts and endothelial cells that are important for the starting of new 
vessels formation [26]. At the end of this phase also intervene the lymphocytes recalled by 
interleukin-1 (IL-1) playing and important role in the collagen remodelling, that is crucial for the 
following phase [25]. 
The third stage of the process takes place within 3-10 days from the injury and continues with the 
migration of different tissue-specific cell to the wound site. This phase is characterized by the 
migration of fibroblasts, new vessels formation (angiogenesis) and the synthesis of new 
extracellular matrix, that replace the deposit of fibrin and fibronectin leading to the formation of 
granulation tissue [25].   
The fourth stage begins 2-3 weeks after lesion, when most of the endothelial cells, macrophages and 
myofibroblasts that have participated in the previous phases, undergo apoptosis, promoting the 
formation of a mass, composed mainly of collagen and proteins of the extracellular matrix [27] that 
will be remodelled in the next phase. This phase may last up to one year or two years, or sometimes 
even much longer periods [28,29]. 
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Figure 1: Phases of wound healing progress and the principal factors involved in the process.  
 
The estimated costs for wound dressing in the next 5 years will grow by 4-7% a year [30], leading 
to an increasing interest in the development of new matrix or scaffold to regenerate the cutaneous 
tissue. 
Recently, many experimental attempts have been done in the field of tissue engineering in order to 
develop medical devices (patches, membranes, etc.) to favour faster healing of the wound [14].  
The ideal wound dressing should have different properties according to the wound requirements. 
These wound dressing are divided into two main groups: the traditional one that played no active 
role during wound healing process and the nanotechnology-based wound dressing, that acts as a 
substrate to load different typologies of biological materials such as antibacterial, anti-inflammatory 
and drug/growth factor [31]. Recently wound dressing containing biological compounds like cells 
or growth factors have been developed as helpful new tool for skin regeneration.  
For every thousand inhabitants there were 12 hospital admissions diagnosed with diabetes, of which 
2 admissions had diabetes as the leading cause of hospitalization. Up to 25% of diabetic patients 
suffer from a foot ulcer during their lives, being the ulceration the major cause of infection and 
amputation. Approximately 50% of diabetic foot ulcers become infected, and 20% of these require 
amputation. In more than 85% of amputations of the lower limbs, the ulcer is a critical aspect of the 
disease in diabetic patients. The incidence of diabetes-related amputation is more than two times 
higher in men than in women, while it is similar among racial and ethnic groups. Approximately 
50% of amputations involves the foot, while 50% are below or above the knee. In particular, in 
Italy, amputations among diabetic patients account for about 60% of all admissions for non-
traumatic amputations (ISTAT data). 
Although the conventional treatment of ulcer in diabetic patient, including the revascularization of 
the limb, leads to ulcer healing in 70% of the patients, within the first year after the surgery the 30% 
of them still need to undergo amputation (ISTAT data). 
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Diabetes is a serious burden on economic budgets of national health systems. The total estimated 
cost of diagnosed diabetes in 2010 has been 11.6 % of total expenditure worldwide, 10% in the 
European Countries and 9% in Italy. 
In Europe it is estimated that approximately 1-3% of the population will suffer from chronic ulcers 
during their lifetime, and this percentage will increase as a result of the gradual elongation of life 
expectancy. The prevalence of skin ulcers in European hospitals range from 5% to 28% of patients 
admitted. Ulcers, in particular those related to the lower limbs, represent a very important clinical 
problem especially for diabetic patients. Approximately 50% of foot ulcers undergo recurrent 
infections that, in 20% of patients lead to amputation of the limb (ISTAT data).  
Chronic injuries not only have a significant impact on public health, but also represent a large 
component of medical expenditures. In Italy, the cost of treating chronic lesions (decubitus wounds, 
diabetic ulcers and surgical injuries) reaches 1 billion euros per year, representing an important 
burden for the health system. 
For these reasons, all health systems, both public and private, pay particular attention to new 
therapeutic strategies for the management of skin ulcers in order to improve patients’ quality of life 
and reducing the costs of therapeutic treatments. However, clinical treatment of chronic ulcers 
remains a problem, especially in terms of complete wound healing process [14]. 
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AIMS OF PhD 
 
Based on our previous manuscripts [15,32], our long-term goal is the development of a new 
therapeutic approach to regenerate the cutaneous tissue by  the use of platelet derivatives. 
The Thesis is divided in three different chapters: 
 
1. Platelet derivative effect on the proliferative stage of mesenchymal stem cells and cell lines, 
and MYC pathway activation;  
2. Electrospun silk fibroin fibers for storage and controlled release of human platelet lysate. In 
collaboration with Dr. Atanassiou’s group of Smart Materials, Nanophysics, IIT of Genoa; 
3. Sericin, alginate and platelet lysate combined in a biomembrane for the treatment of skin 
ulcers. In collaboration with Dr. Torre’s group of University of Pavia from the department of 
Drug Science. 
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1. PLATELET DERIVATIVES EFFECT ON THE 
PROLIFERATIVE STAGE OF MESENCHYMAL STEM CELLS 
AND CELL LINES AND MYC PATHWAY ACTIVATION.  
 
ABSTRACT 
The present paper is related to the field of cell culture medium supplements. In particular, it refers 
to (i) an heparin-free human Platelet Lysate devoid of serum or plasma components (v-PL) and (ii) 
an heparin-free human serum devoid of platelet lysate components (Pl-s), and to their use as single 
components or in combination in primary or cell line cultures. 
Human Mesenchymal Stem Cells (MSC) primary cultures were obtained from adipose, bone-
marrow and umbilical cord. The cumulative cell doubling number in the presence of the different 
culture medium supplements was determined at different culture times. In general, MSC expanded 
in the presence of Pl-s alone showed a low or no proliferation in comparison to cells grown with the 
combination of Pl-s and v-PL. Confluent, growth arrested cells, either human MSC or human 
articular chondrocytes, treated with v-PL resumed proliferation, whereas control cultures, not 
supplemented with v-PL, remained quiescent and did not proliferate. Interestingly, signal 
transduction pathways distinctive of proliferation were activated also in cells treated with v-PL in 
the absence of serum, when cell proliferation did not occur, indicating that v-PL could induce the 
cell re-entry in the cell cycle (cell commitment), but the presence of serum proteins was an 
indispensable requirement for cell proliferation to happen. Indeed, Pl-s alone supported cell growth 
in constitutively activated cell lines (U-937, HeLa, HaCaT, V-79) regardless the co-presence of v-
PL. Plasma and plasma-derived serum were equally able to sustain cell proliferation although, for 
cells cultured in adhesion, the Pl-s was more efficient than the plasma from which it was derived. 
Moreover, cell expanded in the presence of the new additives maintained their differentiation 
potential and did not show alterations in their karyotype. 
In a different work we showed how Platelet Lysate (PL) derived from Platelet Rich Plasma (PRP) 
was capable to support growth and isolation of MSC (Mesenchymal Stromal Cell). However, the 
molecular mechanisms involved in these processes were still unknown. We focused our attention on 
a family of highly conserved proteins involved in different cellular mechanisms such as cell growth, 
proliferation and apoptosis, MYC's family. In particular, MYC is a transcription factor that activates 
or inhibits the transcription of several genes by interacting with other proteins. 
The three proteins of C-MYC gene have the same c-terminal part, differing in the N-terminal region 
due to an alternative translation at the start site. The three forms are C-MYC1, C-MYC2 and C-
MYCS, differently expressed during cell growth. 
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INTRODUCTION 
Platelet growth factors can support cell proliferation and differentiation and human platelet 
derivatives were proposed as tissue culture supplements alternative to Fetal Calf or Fetal Bovine 
Serum (FCS or FBS). The adoption of an animal–free culture medium is particularly relevant in 
establishing culture conditions for isolation and expansion of cells intended for clinical applications. 
Platelet derivatives used as cell culture medium supplements, are commonly provided in the form of 
platelet-lysate (PL) within a small amount of plasma.  
Plasma is the physiological fluid of blood, while serum is the fluid remaining from plasma after 
fibrinogen, prothrombin, and other clotting factors have been removed. In vivo, cells are normally 
exposed to plasma and come in contact with serum only at the time of clot formation following an 
injury. Though, the use of plasma in cell culture presents some problems. Citrate, a calcium 
chelator, is the standard plasma anticoagulant used in the process of blood and plasma collection, 
but, fibrin clots may still form when plasma is added to culture media, which contain calcium [33]. 
This is often prevented by adding heparin to the platelet lysate [34]. However, heparins are active 
factors that bind growth factors and may interfere with cell growth [35–38]. Heparin negatively 
affected proliferation and motility of vascular smooth muscle cells [39,40] and inhibited growth of 
osteoblasts and Mesenchymal Stem Cells (MSC) under conventional culture conditions [41–43]. It 
was also shown that a relatively high concentration of heparin in culture media supplemented with 
human platelet lysate (PL) impaired adipogenic and osteogenic differentiation of MSC [44]. Others 
reports showed that heparin interfered with the functional capacity for migration and homing of 
bone marrow (BM)-derived mononuclear cells used in cardiovascular repair [45]. Moreover, 
commercially available heparin is manufactured primarily from porcine sources and, being of 
animal origin, it represents a limit in the development of a totally xeno-free medium. Although 
porcine heparin is approved for human use, there are examples of hypersensitivity to the molecule 
[46,47]. 
To overcome the need of heparin to prevent clotting after PL addition to the culture medium, 
different options, including the use of serum, were proposed. In principle a human serum could be 
obtained by letting fresh whole blood, collected without any anticoagulant, to clot several hours 
before high-speed centrifugation. Being deprived of coagulation factors, this serum, containing also 
platelet factors, can be added to the cell culture medium without that fibrin clots may form. 
However, this method yields only small aliquots of PL, suitable mainly for research use. In fact, this 
type of strategy does not allow the preparation of large batches of standardized, quality controlled 
PL starting from outdated blood donations. Indeed, an adopted approach is the production of a 
serum-converted PL from pooled Platelet Rich Plasma (PRP) derived from buffy coats, i.e. 
fractions of blood which are by-products of plasma preparations routinely performed in the Blood 
Banks. The plasma-coagulation step is performedd by the addition of calcium chloride and/or 
thrombin (in most cases of animal origin). However, by this procedure the relative concentration of 
factors before and after coagulation can vary. When the concentration levels of 100 soluble factors 
were measured in plasma and serum using a multiplexed ELISA assay, a comparison revealed that 
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concentrations of 2 factors were higher in plasma, whereas the concentrations of 18 factors, 
including 11 chemokines, were higher in serum [33]. Conflicting results exist in the literature with 
regard to the comparison of the biological activities of plasma and its derived serum. Mojica-
Henshaw et al reported that PL-serum was less efficient than the sister counterpart PL-plasma in 
supporting MSC proliferation although both lysates supported the cell tri-lineage differentiation 
potential [48]. A beneficial effect of the fibrinogen depleted lysate was instead observed with regard 
to the immunosuppressive properties of MSC [49].  
An additional possibility to avoid the use of heparin, is the production of a PL devoid of plasma 
through repeated cycles of platelet washing with a saline solution prior their rupture and release of 
bioactive factors. This PL sustained cell proliferation, comparable to FBS, in short term (1-7 days) 
cultures of renal epithelial cells, of either animal or human origin, in adhesion as well as of human 
lymphoblastoid cells in suspension [50]. The mitogenic effect induced by the PL addition was 
confirmed also by the activation of the ERK1/2 factors. However, the sustainability of long term 
cell expansion in the presence of PL obtained from washed platelets was not investigated and no 
experimental evidence was given in the published reports of a long term cell culture in the 
continuous presence of a plasma-free or serum-free PL as the only medium supplement. 
As mentioned above, serum is usually obtained by allowing a whole blood specimen to clot prior to 
centrifugation. The first studies, using human serum obtained by conventional blood coagulation as 
cell culture supplement, showed the efficient isolation and expansion of bone marrow MSC that 
maintained their osteo-adipogenic differentiation potential (osteogenic differentiation was higher in 
autologous serum rather than in FBS) [51]. Furthermore, bone marrow derived MSC expanded in 
the presence of autologous human serum from whole blood presented a higher cell motility 
compared to the ones expanded in the presence of FCS [52]. Autologous serum was shown to be a 
suitable supplement also for the in vitro expansion of dental pulp stem cells without altering their 
multi-lineage differentiation ability [53]. In some cases, serum was also successfully derived by the 
clotting of umbilical cord whole blood. Human MSC from bone-marrow and umbilical cord, 
isolated and expanded in allogenic cord blood serum (CBS) displayed higher self-renewal and a 
delayed senescence compared to cells cultured in fetal bovine serum, [54]. Moreover MSC cultured 
in the presence of CBS showed an enhanced and accelerated osteogenic differentiation and a 
repressed adipogenic differentiation [55]. Off the clot AB serum is commercially available and was 
successfully used for isolation and expansion of cells, such as bone-marrow MSC and 
hematopoietic stem cells [56,57]. Human AB-serum was successfully used also for adipose MSC 
long-term culture [34]. Contradictory results however have been reported on the use of allogeneic 
human serum [58–61].  
 
Alternatively, serum can be derived from blood plasma that has been treated with anticoagulants 
and from which blood cells, including red blood cells, white blood cells and platelets, were 
removed by centrifugation (Platelet Poor Plasma; PPP) or by plasma directly collected by apheresis. 
Also in this case, coagulation is obtained by addition of calcium cations and/or thrombin treatment. 
However, depending on the protocols to obtain the PPP, preparations may contain residual platelets. 
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These residual platelets are activated during the centrifugation steps and the coagulation process 
and undergo a degranulation of the alpha granules, resulting in the release of their growth factor 
content. Therefore, the level of platelet growth factors in the final serum may change depending on 
the presence of platelets in the source material and this may significantly change the biological 
effect of serum when used as supplement in a cell culture medium. Tanaka et al. described a more 
pronounced stimulation of proliferation of human articular chondrocytes when a serum derived 
from plasma including platelets was compared to a serum derived from a plasma depleted of 
platelets although no significant differences were observed on the cartilage matrix deposition by 
chondrocytes cultured under the different serum conditions [62]. Recently, a comparison was 
performed between two different plasma sources to obtain human serum, plasma removed from 
blood after 24 h from collection and plasma devoided of cryoprecipitate. Serum was obtained after 
coagulation in the presence of calcium ions. Both forms of plasma-derived serum were effective in 
sustaining fetal umbilical cord matrix derived MSC proliferation as the standard supplement bovine 
serum [63]. 
The different abilities of plasma and serum to modulate cell growth were already investigated 
already in the ‘70s. Initial studies indicated that cells did not proliferate in plasma containing 
medium, but they proliferated actively when they were exposed to serum [64]. However the initial 
comparison was made between platelet-free plasma and serum containing platelet mitogens. Indeed, 
the addition of platelets and calcium to platelet-free plasma increased the activity of the obtained 
plasma serum to the same level achieved with blood serum [65]. Also the tridimensional 
environment to which cells are exposed to is crucial in modulating cell behavior. Gospodarorowicz 
and Ill reported that bovine vascular smooth muscle cells in Petri dishes exposed to plasma 
proliferated poorly compared to when exposed to serum from whole blood, but, when the same cells 
were seeded on  extracellular matrix (ECM) coated dishes, they proliferated equally well in the 
presence of either plasma or serum [66]. Since this pioneering work, taking advantage of different 
cell types, different substrates and different culture conditions, other authors have investigated the 
abilities of plasma and serum to promote cell growth [51,59,67]. Although published results are 
sometimes contradictory, some general conclusions can be made out of these publications: (i) 
platelet depleted plasma or serum derived from this plasma are poor cell growth inducers in cultures 
of primary cells [65,68,69]; (ii) serum allows a better adhesion of the cells to the substrate than 
plasma, unless a coating of the culture dishes by serum or extracellular matrix proteins is adopted. 
Several years ago, Rutherford et al. reported that exposure of quiescent cells to whole blood serum 
or platelet-free plasma serum plus crude platelet factors preparations stimulated cell proliferation 
[70]. However, no accurate investigations were ever done to distinguish between the role played by 
factors and molecules released by platelets and the serum components. We report that, although 
factors and molecules released by platelets (PL in saline solution) were capable of activating the 
cell proliferation machinery (ERK and AKT phosphorylation, Cyclin D1 induction, etc.) and of 
recruiting quiescent, and even differentiated or senescent cells back in the cell cycle, the PL itself 
was unable to support cell proliferation unless the plasma or serum components were also present in 
the culture medium. Interesting, in cells that were constitutively stimulated, such as different cell 
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lines of human or animal origin, or in some cultures of cells derived from fetal tissues, the addition 
of PL to the culture medium was not an absolute requirement and cell proliferation could be 
obtained by the simple addition of PL-free serum. 
To fill this gap, we studied the molecular mechanisms underlying the effects of PL on proliferation 
of the primary cell culture and cell lines we focused the study on molecular mechanisms that are at 
the base of this result. From previous works we know that stimulation with PL activated the 
phosphorylation of some genes involved in cells proliferation [71,72] like ERK, AKT and Cyclin 
D1. Given the critical role of MYC gene family in the cell proliferation, we evaluated the expression 
of C-MYC gene, in cell primary cultures derived from adult and fetal tissues and cell line. [73]. 
The human C-MYC is translated into three different isoforms that give rise to three corresponding 
protein products: C-MYC1, C-MYC2 and C-MYCS. The C-MYC protein plays a critical role in 
cellular proliferation, cell size, differentiation, stem cell self-renewal and apoptosis [74]. This gene 
encodes preferentially for the two major nuclear proteins that are found in the species ranging from 
Xenopus to human [75]. The most abundant protein is represented by C-MYC2, that initiates his 
translation in exon 2 from the first AUG codon, whereas C-MYC1, starts upstream in exon 1 at a 
non-AUG site. These two proteins were identified in 1984 [76], using antiserum prepared against a 
synthetic peptide corresponding to the C-terminus  of human C-MYC sequence. They identified two 
protein of 64 and 67 kD as the major products of C-MYC gene. Hann et al. in 1988 [75] 
demonstrated that this two proteins are derived from alternative translational initiations in the same 
reading frame in exon 1 and 2. 
In 1997 Spotts at al. [77] reported that human, murine, and avian cells express smaller C-MYC 
proteins in addition to the full-length C-MYC1 and 2 protein. These proteins, called C-MYCS, 
similarly to full-length protein appeared to be localized in the nucleus. The synthesis of these 
proteins, in contrast with C-MYC1 and 2, is transient during growth [77].  
The three proteins have the same C-terminal part, differing in the N-terminal region [78] due to an 
alternative translation at the start site. These three forms are differently expressed during cell 
growth: the C-MYC2 protein, preferably expressed in proliferating cells [75]; the C-MYC1 form, 
which prevails in cells that break the growth due to the high density or lack of methionine [79,80]; 
the C-MYCS form, present in vertebrate cells, is transiently present [77] and less abundant. 
In PL culture condition the C-MYC1 isoform appeared to be modulated respect to the standard, 
showing an increment, contrary to what is shown in the literature, in which C-MYC1 is expressed 
only under conditions of cellular stress. In this regard we evaluated the activation of this isoform in 
critical culture condition in presence and absence of PL. Cells stimulated with PL showed 
expression of C-MYC1 in a proliferative step also when they were cultured at low confluence and 
at high methionine concentration in the medium, condition in which C-MYC1 should not be 
activated.  
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MATERIALS AND METHODS 
 
Production of virgin-Platelet Lysate (v-PL) and Plasma-serum (Pl-s) 
An outline of the manufacturing process is reported in Figure 1. All separation steps were 
performed within a sterile closed system. The high-speed centrifugation of a whole blood unit 
separates different phases: the plasma at the top, the buffy coat (BC) layer (enriched in platelets and 
leukocytes) at the interface and the red blood cells fraction at the bottom. For the preparation of the 
virgin-Platelet Lysate (v-PL), pools of BC units (not usable for transfusion purposes; up to 300 total 
units) were centrifuged at low speed. The Platelet Rich Plasma (PRP) was recovered from the upper 
part of the blood bag and high-speed centrifuged to separate an upper phase, the Platelet Poor 
Plasma (PPP) and a lower phase, the platelet concentrate. Recovered platelets were subjected to 
three washes in sterile saline solution. After the third wash, the platelet concentrate was suspended 
in saline solution and the platelet concentration adjusted to 10 x106 plt/µL. The platelet concentrate 
underwent three freeze-thaw cycles. A high-speed centrifugation was then performed to sediment 
platelet membranes and debris. The different obtained supernatants, the plasma-free Platelet Lysates 
(v-PL) were combined in a single pool before being divided into aliquots and lyophilized. 
The Plasma-serum (Pl-s) was obtained from several frozen plasma units. Each plasma unit was 
slowly thawed at 4°C to separate the cryoprecipitate and the cryo-poor plasma (CPP). The CPP was 
added of calcium chloride (2 mg/ml) and then subjected to a coagulation step at 37°C up to 6 hours. 
After the coagulation step, the blood bag was high-speed centrifuged to separate the coagulum. The 
liquid phase, the Plasma-serum (Pl-s), was recovered, and the pool of several units was divided into 
aliquots and lyophilized.  
 
Cell culture 
Adult mesenchymal stem cells 
Human bone marrow stromal cells (BMSC or BM-MSC) were obtained from discarded adult 
femoral heads of patients undergoing orthopaedic surgery for hip prosthesis, with the approval of 
the Institutional Ethic Commitee of San Martino Hospital (Genoa, Italy). The bone marrow was 
washed 5 times with PBS 1X. The obtained liquid was centrifuged at 1500 rpm for 10 minutes at 
room temperature (RT). The supernatant was discarded while the pellet was recovered and re-
suspended in a quantity of α-MEM (Lonza, Belgium) so that it had an adequate cell count (50-100 
nucleated cells per square in Burker's chamber). Counting was carried out using a nuclear dye 
(0.1% methyl violet in 0.1M citric acid). After counting, the cells were plated at a consonant 
density. The only cells that will be able to adhere to the plate will be those of our interest (BMSC). 
The cells were cultivated in α-MEM.  
 
Human adipose tissue cells (ADAS or AD-MSC) were obtained by treating lipoaspirate samples 
derived from discarded liposuction performed in adult patients with the approval of the Institutional 
Ethic Commitee of San Martino Hospital (Genoa, Italy). The sample was washed 4-5 times with 
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PBS 1X and subsequently digested with an enzymatic solution (type I collagenase 0.1% in PBS 1X) 
at 37 °C for 1 hour vigorously agitating every 15 minutes to facilitate digestion. 
The sample was then centrifuged twice at 1200 rpm for 5 min at RT, re-suspending the pellet 
between both centrifugations. After centrifugation, three different phases were obtained: the supper 
and the intermediate, containing fat cells and the enzymatic aquous solution, respectively, were 
discarded. The stromal vascular fraction (SVF) containing mesenchymal stromal cells was re-
suspended in 5 mL of α-MEM supplemented with 10% FBS in order to inhibit the activity of any 
remaining enzyme activity. The resulting solution was again centrifuged under the same conditions 
and the new pellet formed was re-suspended in in basic medium to remove the remaining traces of 
FBS. After a subsequent centrifuge under the same conditions as described above, the pellet 
obtained was re-suspended in a volume of medium corresponding to the initial volume of 
lipoaspirate. The sample was cultivated into flasks in α-MEM.  
 
Fetal stem cells 
Human amniotic fluids stem cells (AFS) were obtained from discarded samples of amniocentesis 
performed at the Cytogenetic Laboratory of Galliera Hospital (Genoa, Italy) for fetal karyotyping, 
between 15 and 17 weeks of gestation with the approval of Ethical Commitee of Galliera Hospital 
(in collaboration with Dr. C. Gentili). Primary cells were isolated from amniotic fluid by 
centrifugation and suspended in Chang Medium. After 5-6 days, non-adherent cells and debris were 
discarded and adherent cells were c-Kit selected by magnetic cell sorting on a Mini-MACS 
apparatus. AFSC were then expanded in α-MEM.  
 
Umbilical Cord derived MSC (UC-MSC) were kindly provided by Dr. M. Introna (AO Papa 
Giovanni XXIII USS Center of Cell Therapy ‘G. Lanzani’ USC Hematology, Bergamo, Italy). Cells 
were isolated from cord blood tissue collected from pregnant women after either normal vaginal 
delivery or cesarean sections. The UC processing was performed in accordance with the protocol 
for the isolation and expansion of UC-MSC as previously described [81]. The cells were cultivated 
in α-MEM. 
 
Other cell types 
Human bone samples (hOB) were obtained from discarded trabecular bone of adult patients 
undergoing orthopaedic surgery with the approval of Ethical Committee of San Martino Hospital 
(Genoa, Italy). The bone sample was cleaned of adherent soft tissue and cut into small pieces, 
washed in Ringer solution and digested at 37 °C by consecutive treatment with 1 mg/mL trypsin for 
10 min; 2 mg/mL dispase for 20 min; 3 mg/mL collagenase type II, for 30 min repeated twice. The 
products derived from the first two digestions were discarded, whereas cells released by the 
collagenase digestions were collected by centrifugation, washed, plated and cultured with Iscove.  
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Human articular cartilage (hAC) was obtained from discarded biopsies from adult patients 
undergoing orthopaedic surgery withg to the approval of Ethical Committee of San Martino 
Hospital (Genoa, Italy). The cartilage sample was cut into small fragments, washed several times 
with PBS and centrifuged at 1500 rpm for 10 min at RT. The supernatant was discarded and 
replaced with an enzymatic solution made of 0.25% trypsin, 400 U/mL collagenase type I, 1000 
U/mL collagenase type II and 1 mg/mL hyaluronidase at 37 °C for 1 h. The supernatant derived 
from the first enzymatic digestion was discarded and the enzymatic digestion steps were repeated 
until the all biopsy material was digested. For each cycle of digestion after the first one, the 
supernatant was collected and the enzymatic activity blocked with Coon’s modified Ham’s F-12 
medium containing 10% FBS. Isolated chondrocytes were then washed with basal medium to 
remove any residual of FBS and then cultured in Coon’s modified Ham’s F-12 medium. In some 
experiments, dedifferentiated chondrocytes were transferred to suspension culture in the presence of 
ascorbic acid to allow the formation of a cartilage-like tissue [82]. 
 
Cell lines 
HeLa cells (human cervical adenocarcinoma) were purchased from Interlab Cell Line Collection of 
the Biological Bank and Cell Factory of the Ospedale Policlinico San Martino (Genoa, Italy). They 
were thawed and plated in Petri plates. Cells were expanded in D-MEM High Glucose (Euroclone, 
Italy).  
 
U-937 cell line (human histiocytic lymphoma) was purchased from the Interlab Cell Line Collection 
of the Biological Bank and Cell Factory of the Ospedale Policlinico San Martino (Genoa, Italy). 
They were thawed and plated in Petri plates. Cells were expanded in RPMI (Euroclone, Italy). 
 
HaCaT cell line (human immortalized keratinocytes) was kindly provided by Dr. G. Pellegrini 
(Centro di Medicina Rigenerativa “Stefano Ferrari” Modena, Italy). They were thawed and plated in 
Petri plates. Cells were expanded in DMEM (Euroclone, Italy). 
 
V-79 cells (lung of Chinese hamster) were purchased from the Interlab Cell Line Collection of the 
Biological Bank and Cell Factory of the Ospedale Policlinico San Martino (Genoa, Italy). They 
were thawed and plated in Petri plates. Cells were expanded in MEM (EBSS). 
 
In all culture conditions, the basal medium was supplemented with 100 IU/mL penicillin and 100 
µg/ml streptomycin, 2 mM L-glutamine and, when indicated, with Pl-s and v-PL used alone or in 
different combinations or with 5% PL (indicated as PL). In some control experiments, medium was 
supplemented with 10% Fetal Calf Serum (FCS, Invitrogen, USA) as control of standard culture 
condition of mesenchymal stem cells, with, in some cases, the addition of FGF-2 growth factor. 
Cells were detached from the culture dish with 0.05% trypsin and 0.01% EDTA (Euroclone, Italy). 
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Trypsin activity was neutralized with a trypsin soybean inhibitor solution (0.5 mg/ml in PBS; 
GIBCO, USA).  
 
BMSC, ADAS, AFS, hOB, hAC and HeLa cells were used also for MYC pathway analyses, after 
reaching confluence, were detached, counted and plated at a density of 70000 cells for a 60 mm Ø 
Petri dishes, while HeLa cells were seeded at  a density of 30000 cells per 60 mm Ø Petri dishes. 
 
Cell proliferation assays 
Long-term cell proliferation assay – Cumulative doubling number calculation 
For determining the number of doublings of BM-MSC, AD-MSC and UC-MSC in a long term 
culture, after the initial selection of the cells (passage 0) in FCS supplemented medium, cells at 70-
80% confluence were detached with trypsin/EDTA solution and replated at the density of 7 x 104 
cells for UC-MSC and 1 x 105 cells for all the other cell types, in 60 mm Ø Petri dishes, in duplicate 
with medium supplemented with 10% Pl-s or 10% Pl-s + 5% v-PL or 10% Pl-s + 1% v-PL. Number 
of doublings were calculated by counting the number of cells at each passage until the end of the 
culture.  
The human cell lines U-937 (pro-monocytic cells growing in suspension), HeLa (epithelial cells 
with adhesion growth), HaCaT (keratinocytes with adhesion growth) and the animal cell line V79 
(hamster lung fibroblasts, also growing as adherent cells) were cultured with the same supplements 
used for the primary cell cultures. To monitor cell proliferation, the cumulative number of 
doublings performed at different culture times was determined. At each passage, cells were plated 
at the following densities: U-937, 2 x 105 cells/mL in T25 flask; HeLa, 2,5 x 105 cells/60 mm Ø 
plate; HaCaT, 2,5 x 10 cells/plate 60 mm Ø; V79, 4 x 10cells/ 60 mm Ø plate. 
Unless differently stated, results were expressed as the average of at least three independent 
experiments. 
 
Short-term cell proliferation assay 
For determining cell proliferation rate during a short time period, BM-MSC, HeLa and U-937 
chosen as representative of primary cell cultures and cell lines growing in adhesion and in 
suspension respectively were plated for BM-MSC at 5 x 104 cells in 6 multi-well plates and for 
Hela, at 1 x 105 cells/60 mm Ø plate. U-937 were seeded at 1 x 105 cells/ml in T25 flask. The 
number of cells was determined at different time intervals during a week. Results were expressed as 
the average of at least two independent experiments. 
 
Cell proliferation assay for articular chondrocytes - Crystal violet staining 
Cells were seeded in 96 multi-well plates and cultured in the presence of different medium 
supplements as indicated. At different times of the culture, after extensive washing with PBS, cells 
were stained with 50 µl staining solution [0.75% (g/ml) crystal violet (Sigma-Aldrich, USA), 0.35% 
(g/ml) NaCl, 32.3% (v/v) absolute ethanol and 8.64% (v/v) formaldehyde 37%] for 20 minutes at 
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RT. Cells were then washed 5 times with water and dried by exposing the plate to air under a 
chemical hood. To each well 100 µL eluent solution [50% (v/v) absolute ethanol and 1% (v/v) 
acetic acid] were added and the absorbance at 595 nm measured within 10-30 minutes with a 
spectrophotometer AD 200 (Beckman Coulter, USA). For each experimental condition 
quintuplicate assays were performed.  Results were expressed as the average of at least three 
independent experiments. 
 
Cell differentiation assays 
Osteogenic differentiation 
Confluent BM-MSC and AD-MSC were cultured in osteogenic differentiation medium containing 
10% Pl-s, 50 µg/ml ascorbic acid, 10 mM ß-glycerophosphate and 10−7 M dexamethasone (all 
from Sigma Aldrich). Negative control cultures were maintained in medium containing 10% Pl-s. 
The medium was changed three times weekly and osteogenic stimulation took place for 3 weeks. 
Alizarin red S staining was performed at the end of the induction period. 
 
Chondrogenic differentiation 
Dedifferentiated chondrocytes were transferred in suspension culture in 15 ml Falcon tubes to 
prevent cell attachment, but still ensuring cell-cell interactions, and in the presence of 100 µg/ml 
ascorbic acid (Sigma Aldrich, USA) to allow the organization of a cartilage matrix and the 
formation of a cartilage-like tissue. Cell aggregates were washed 3 times with PBS, fixed with 3.7% 
paraformaldehyde (PFA) for 20 minutes at 40 °C and embedded in paraffin. Paraffin embedded 
samples were sectioned in slices of 5-6 µm thickness. Slices were adhered on Superfrost Ultra Plus 
Slides (Thermo Scientific, Germany) coated with poly-L-lysine (Sigma Aldrich, USA), dewaxed to 
remove paraffin and processed for immunohistochemistry.  
Sections were permeabilized with 0.2% Triton in PBS for 10 minutes, treated with 4% H2O2 for 30 
minutes at room temperature (RT) to inhibit endogenous peroxidase activity, rinsed with PBS 3 
times x 5 minutes, incubated with hyaluronidase type II (Sigma Aldrich, USA) at concentration of 1 
mg/ml in PBS (pH 6) for 30 minutes at 37 °C and washed with PBS. After incubation with 10% 
normal goat serum in PBS for 1 hour at RT to inhibit nonspecific binding, the sections were 
incubated at 40 C for 16 hours with primary antibodies against α-collagen type II (1:100; CIIC1-
Developmental Studies Hybridoma Bank, University of Iowa), washed 3 times with PBS and 
incubated for 1 hour at RT with Labeled polymer HRP anti-mouse (Dako, Denmark). Sections were 
stained with 3,3'-Diaminobenzidine	(DAB, Enzo Life Sciences, USA) for 3-5 minutes, counter-
stained with Mayer’s hematoxylin for 2 seconds, submersed in 0,1% NaHCO3 for 1 minute, and 
finally mounted with Eukitt (O. Kindler GmbH, Germany). Images were acquired by a microscope 
Axiovert 200M (Carl Zeiss, Germany).  
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Molecular analysis 
Protein extraction 
For western blot (WB) analysis, the cells used for the C-MYC analysis were exposed to cell lysis 
that was performed on cells that have reached 80% of their confluence, to avoid detachment during 
collection process. 
The plates were placed on ice during the whole process. The medium was removed from the cells 
and then they were washed with cold PBS 1X. A lysis buffer (500 µL per 60 mm Ø plate) was 
added to each plate. Concurrently to the lysis buffer, phosphatases and proteases inhibitors 
(PhoStop and Complites) were added to avoid the protein degradation. 
The lysis buffer was allowed to act for 5 minutes, always keeping the plate on ice. Then, the cells 
were dislodged from the bottom of the plate and collected all within a 1.5 mL eppendorf. The 
eppendorf was placed on ice for 40 minutes and was vortexed every 10 minutes. At the end of the 
incubation the samples were centrifuged at 4 °C for 20 minutes at 13000 rpm. The resulting cell 
pellet was discarded while the supernatant containing the proteins was aliquoted for protein analysis 
by WB. 
Cells, whose lysates were subjected to WB, were treated in several ways. Some cells were directly 
isolated in presence of platelet derivatives used at the appropriate percentage depending on cell 
type. Other cells were plated in the 10% FBS condition. Some of the plates in the 10% FBS 
condition, after reaching 60% confluence, were switched to platelet derivatives at the appropriate 
percentage, collected at 5 minutes, 30 minutes, 1 hour and 24 hours, and processed as described 
above. 
 
Methionine stimulation 
HeLa cells were, for preliminary experiments, stimulated with lower doses of methionine (30,60, or 
90 mg/L) and for subsequent experiments with a solution of methionine 5-10 mM. Cells were 
plated in 60 Ø mm Petri dishes (two plates for each condition). Methionine was added at several 
concentrations to the supplemented base medium (10% FBS or 5% platelet derivatives). All 
conditions were monitored during proliferation by microscopic acquisition. When sub-confluence 
was reached, the cells were collected and lysed as described above. 
 
Western blot analysis  
Confluent dedifferentiated chondrocytes were supplemented with 5% v-PL either in presence or 
absence of bovine serum. At different times after the addition of the supplement, cells were washed 
with phosphate buffered saline (PBS) and collected for western blot analysis.  
The protein content of cell lysate, was determined by Bradford assay and after quantification WB 
analyses were performed.  
Electrophoresis was performed in reducing conditions using 20-70 µg of protein loaded on a 4-12% 
NuPAGE Bis-Tris gel (Invitrogen, USA) and proteins were transferred to a AmershamTM 
ProtranTM 0.45 µm NC nitrocellulose blotting membrane. The blot was saturated with 5% 
		20	
skimmed cow milk in TTBS (20 mM Tris HCl pH 7.5, 500 mM NaCl, 0.1% Tween 20) for 2h at 
RT and washed several times with TTBS and and then incubated in a cold room overnight with 
antibodies specific for pERK (1:1000, Cell Signaling), ERK (1:1000, Cell Signaling) pAKT (1:500, 
Cell Signaling), AKT (1:1000, Cell Signaling), Cyclin D1 (1:250, Santa-Cruz Biotechnology) and 
Actin (1:500, Santa-Cruz Biotechnology). For C-MYC analyses membranes was also incubated 
with specific antibody against C-MYC (1:1000, DSHB). After incubation, with the primary 
antibody, the membrane was washed with TTBS at RT for 1h and incubated with 1:5000 
Mouse/Rabbit specific HRP-conjugated secondary antibody. The bands of WB were detected with 
enhanced chemiluminescent (ECL) and exposed to an X-ray film (GE Healthcare). 
Images were scanned using the Epson perfection 1260 scanner (Epson, Italy) and band densities 
were quantified using the ImageJ software (NIH, USA, http://rsbweb.nih.gov/ij/download.html). 
Western blots were performed on three different independent primary cultures. 
 
Karyotype analysis 
Forty thousand BM-MSC expanded in medium containing 10% Pl-s + 1% v-PL were plated in slide 
flasks (Thermo Fisher Scientific, Denmark) and cultured at 37°C in 5% CO2 atmosphere. After 1-2 
days the medium was replaced with 2,5 mL of fresh medium containing Colcemid solution 
(6µg/mL; Sigma Aldrich, USA) and incubation continued.  After 2 hours of incubation, the medium 
was removed and replaced with 5 mL of hypotonic solution [tri-Sodium citrate dehydrate 17 
mM/potassium chloride 75 mM (1:1) solution] followed by an incubation of 10 minutes. Then, that 
0,5 mL of fixative ethanol/acetic acid (3:1) solution were added to the flask for 10 minutes at RT. 
The solution was then removed and replaced by 2,5 mL of fresh fixative followed by an incubation 
of 15 min (repeated three times). 
Chromosome staining was performed by Q-banding technique (Quinacrine stain, DBA Italia, Italy). 
Each slide was examined and photographed under a fluorescence microscope (Olympus) using 
software MACTYPE 5.4.1 (Apple). A minimum of 10 metaphases for each sample were captured 
and analysed. 
 
Growth factors quantification 
The platelet growth factors were quantified by an ELISA assay on Pl-s and v-PL. The adopted kits 
were from RayBiotech (USA) for PDGF-BB and from Invitrogen (USA) for VEGF respectively. 
The assays were performed according to the manufacturer directives. 
 
Immunofluorescence analysis 
Cells were grown on 1 cm Ø sterile slides placed on the bottom of a 24-well plate. The cells were 
fixed with paraformaldehyde (PFA) 3.7% at RT for 10 minutes. All subsequent steps were carried 
out on ice as well as all the solutions and reagents used. Once the cells were fixed, they were 
washed with PBS and treated with a permeabilizing solution (HEPES 20 mM, NaCl 50 mM, Triton 
x-100 0.5%, MgCl2 3 mM and saccarose 300 mM) for 5 minutes. Then the slides were washed with 
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PBS for 5 minutes and treated with 20% normal goat serum in PBS 1X for at least 30 minutes. 
After blocking, cells were incubated with primary antibody against Ki67 (1:4000, Oncogene) for 2 
hours at 4 °C. Subsequently, hybridization was performed with specific fluorescent secondary 
antibody (mouse 1:800). Prior to final assembly, the slides were incubated with HOECHST 
(1:5000), a fluorescent blue dye used to mark the DNA and then highlighting the nuclei of cells. 
Slides were mounted on object-mounted slides with an aqueous mounting and subsequently 
analyzed at different magnifications, using a fluorescence microscope. 
 
Apoptosis assay 
The apoptosis assay was performed using Vybrant® Apoptosis Assay Kit (Molecular Probes) with 
sligh modification. We induced apoptosis in control cells, putting them at 96 °C for 10 minutes. All 
the cells (control and other cells), were centrifuged, and the supernatant was discarded, and each 
pellet was re-suspended in 1X annexin-binding buffer (provided by the kit) at a concentration of 
1*106 cells/mL. We added 5 µL of Annexin-APC (BD), 1 µL of the 50 uM C12-resazurin working 
solution and 1 µL of 1 mM Sytox Blue stain working solution to each 100 µL of cell suspension. 
We incubated the cells at 37 °C in an atmosphere of 5% CO2 for 15 minutes. After the incubation 
period, we added 400 µL of 1X annexin-binding buffer, and we kept them on ice. 
We analysed the stained cells by flow cytometry, measuring the fluorescence emission at 530 nm, 
575 nm and 660 nm.  
 
Statistical analysis 
All the experiments, when it was possible, were conducted in triplicate on different primary cell 
cultures. Statistical analyses were performed using Student’s t-test to compare two groups or two-
way ANOVA to assess statistical differences among several groups, provided by the Graphpad 
Software (www.graphpad.com). 
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RESULTS 
 
CELL PROLIFERATION 
 
Growth factors quantification in the v-PL and the Pl-s  
v-PL and Pl-s were produced according to the protocol described in Materials and Methods and 
outlined in Figure 1. An ELISA assay was performed for the quantification in the two culture 
medium supplements of PDGF-BB and VEGF as representative indicators of platelet factors 
present in a relatively high and relatively low concentration respectively (Table I).   
 
Stimulation of cell proliferation by v-PL: primary cell cultures vs cell lines 
Primary cultures of cells derived from adult tissues, AD-MSC (from adipose) and BM-MSC (from 
bone-marrow) or from a fetal tissue, UC-MSC (from umbilical cord) were initially isolated and 
expanded in 10% FCS (passage 0). At the time of the first passage the culture medium was replaced 
with medium supplemented with Pl-s and v-PL in different relative ratios (10% Pl-s or 10% Pl-s + 
1% v-Pl or 10% Pl-s + 5% v-PL) and the cultures continued by passaging the cells before they 
reached confluency for about 30 days. By the evaluation of the cumulative number of population 
doublings performed in the different culture conditions, the following conclusions were inferred: (i) 
In general, cells cultured with Pl-s alone showed a low or no proliferation rate in comparison to 
cells grown with the combination of Pl-s and v-PL; (ii) In particular, BM-MSC essentially did not 
proliferate in the presence of Pl-s alone (about 2 cell doublings in 30 days) whereas underwent 10.5 
and 17 cell doublings in 10% Pl-s + 1% v-PL and 10% Pl-s + 5% v-PL culture medium  
respectively; (iii) whereas AD-MSC and UC-MSC performed about 10 doublings in 10% Pl-s and 
about 25 and 20 doublings in the presence of Pl-s and v-PL respectively; (iv) For both AD-MSC 
and UC-MSC no major differences were observed between the condition 10% Pl-s + 1% v-PL and 
10% Pl-s + 5% v-PL (Figure 2). 
The same culture medium supplements, used in the same combinations as for the primary cell 
cultures, were tested with human, U937, HeLa, HaCaT and animal V-79 cell lines. Also in this case 
the cell proliferation was monitored by determining the number of cell doublings at different culture 
times. v-PL was not required to support cell proliferation. Indeed, Pl-s alone was able to support 
human cell growth in a manner comparable to the different combinations of Pl-s and v-PL both for 
suspension (U-937) and adhesion (HeLa and HaCaT) cultures. Moreover, the human additives 
sustained survival and proliferation of animal derived cells (V-79, growing in adhesion) comparably 
to human cells (Figure 3). 
 
v-PL promotes re-entry in the cell cycle of confluent resting cells  
Confluent growth-arrested dedifferentiated human articular chondrocytes were maintained in the 
original culture medium supplemented with 10% FCS or additionally supplemented with 5% v-PL. 
A crystal violet proliferation assay was performed in parallel on both cultures (Figure 4 upper 
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panel). Confluent cells treated with v-PL resumed proliferation, whereas the control culture 
maintained in FCS only remained quiescent and did not proliferate. 
A western blot analysis of proteins extracted from control cells and cells treated with 5% v-PL for 
different times (1, 4, and 8 hours) was performed using α- cyclin D1, α- phospho Akt, α- phospho 
Erk1/2 antibodies. Actin was blotted as an internal control. After 1 hour from the v-PL treatment, 
we observed an increase in the amount of phospho Akt and phospho Erk1/2 (Extracellular signal-
regulated protein kinases 1 and 2). After 8 hours the activation of these proteins was almost 
completely over. Instead at the same time an expression of the Cyclin D1 protein reached its 
maximum. Interestingly, the western blot analysis also showed that these proliferation pathways 
were activated by PL not only in cells resuming proliferation, but also in cells treated with v-PL in 
the absence of serum (Figure 4 bottom panel).  
This confirmed and expanded our previous observation that confluent quiescent osteoblasts [72] 
that did not proliferate when maintained in serum, once exposed to the PL mitogenic stimulus were 
able to activate signal transduction pathways that promoted cell growth in response to the 
extracellular signals.  
 
v-PL can rejuvenate a culture of senescent MSC 
The positive effect of v-PL on resting cells was confirmed on a primary culture of BM-MSC 
(Figure 5). Cells, isolated and expanded in 10% FCS for about 10 population doublings, were split 
and transferred to different culture conditions: (i) 1% v-PL; (ii) 10% Pl-s; (iii) 10% Pl-s + 1% v-PL. 
Both the 1% v-PL only and the 10% Pl-s only culture conditions were not permissive for the cell 
growth and did not support cell proliferation. However, the combination of the two supplements 
allowed a good proliferation rate. After about 7 doublings, to half of the growing cells the v-PL was 
removed, leaving the cells in 10% Pl-s only. The cells maintained in 10% Pl-s + 1% v-PL remained 
fully viable and continued to grow up to about 25 duplications. On the contrary, in the half culture 
where the mitogenic stimulus of v-PL was removed, the cells, after a period of adaptation to the 
new condition, stopped growing and entered a senescent status. At this point, half of this culture 
was maintained in 10% Pl-s only, whereas the other half was transferred again to 10% Pl-s + 1% v-
PL (restoring in this way the mitogenic stimulus of the v-PL). When v-PL was provided, senescent 
MSC resumed proliferation (Figure 5).   
 
Pl-s versus plasma 
A comparison of the efficacy of Pl-s and plasma in sustaining cell proliferation was performed 
taking advantage of primary cultures of BM-MSC and different cell lines growing either in 
adhesion (HeLa) or in suspension (U-937) (Figure 6). Plasma and plasma-derived serum were 
equally able to sustain cell proliferation. However, especially for BM-MSC and HeLa, both cell 
types growing in adhesion, the Pl-s was slightly more efficient than the plasma from which it was 
derived. 
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Population doublings of cells cultured with the new supplements versus FCS 
AD-MSC were initially isolated and expanded in a medium containing either the standard animal-
based 10% FCS or 10% Pl-s + 1% v-PL (Figure 7). Cultures were monitored for about 30 days and 
the population doublings were calculated. Cells grown with 10% FCS performed a significant lower 
number of doublings in comparison to the parallel culture maintained in 10% Pl-s + 1%v-PL (6 vs 
22 doublings respectively).  
 
Differentiation potential of cells cultured with the new supplements 
Maintenance of the differentiation potential by the cells expanded in the presence of the new 
medium supplements was confirmed. Specific in vitro assays routinely performed in the lab were 
adopted. In particular, osteogenic differentiation was tested for BM-MSC and AD-MSC and 
chondrogenic differentiation for dedifferentiated articular chondrocytes. Representative images of 
the Alizarin Red S staining of MSC and of the type II collagen immunolocalization in the 
chondrocyte culture are presented in Figure 8. In the stimulated culture condition, it is clearly 
evident a calcium enriched matrix and a type II collagen positivity for the MSC and the 
chondrocytes respectively. 
 
Karyotype stability of cells cultured with the new supplements 
Cytogenetic analysis was performed on passage 2 of 3 cultures of BM-MSC in 10% Pl-s + 1% v-
PL, in order to obtain information on the genetic stability of the cells grown in this condition. One 
of the cultures was also analyzed after a more extensive expansion in the presence of the new 
supplement (passage 7). The genetic stability was confirmed in all cultures (Figure 9 and Table II). 
 
MYC MOLECULAR ANALYSIS 
 
Evaluation of protein pathway involved in cell cycle 
The cell systems on which this project is intended to work are all the primary cell cultures derived 
from discarded adult or fetal tissues, according to the guide lines of the Ethical Commitee of San 
Martino Hospital: BMSC or BM-MSC (Bone Marrow Stromal Cell), AD-MSC or ADAS (Adipose 
Derived Mesenchymal Stromal Cells), hOB (human Osteo Blast) hAC (human Articular 
Chondrocyte) hAFS (human Amniotic Fluid Stem cells). Regarding the cell line, we have tested the 
effect of PL on several cell types and obtained reproducible results among all of them, therefore, for 
the next experiments we decided to work only on HeLa cells (human cervical cancer cells). In these 
experiments all cells were treated with 10% FBS and 5% PL from isolation FBS as control 
condition or expanded in FBS and subsequently treated at different times with PL. 
We investigated the different gene expression on MSCs undergoing the two treatments 
(control/stimulated). In agreement with one of our previous our manuscripts [72], we showed that 
phosphorylation of ERK and AKT protein was influenced by PL stimulation. The ERK protein in 
its phosphorylated form, is involved in various processes such as cell adhesion, mitosis, meiosis and 
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post-mitotic functions. AKT protein is also involved in various processes such as glucose 
metabolism, apoptosis, cell proliferation, transcription, and cell migration. (Figure 10) 
 
At the same time, we evaluated the protein produced by the C-MYC gene encoding for a 
transcription factor also involved in different cellular processes such as growth, differentiation and 
apoptosis [49-52].We focused on this gene because preliminary analysis by western-blot on BMSC 
and AD-MSC cells showed the presence of a double band in PL treated samples at both short and 
prolonged time of treatments (Figure 11) when blots were incubated with an antibody against C-
MYC protein. As suggested by the available literature, these two bands do not correspond to an 
unspecific recognition by antibody used, but reflect the existence of two isoforms of the same 
protein. 
 
The lower band, equally present in all samples, represents the most well-studied C-MYC2 protein, 
while the upper band, which is only apparent in samples treated  with PL, even for very short times, 
corresponds to the protein (which differs from only 3 kD) C-MYC1 [75]. This result was evident 
also in all other primary cell types analysed as showed in Figure 12. 
In hOB cell culture we analysed the expression of C-MYC1 in low and high cell confluence to 
evaluate the C-MYC modulation as reported in literature [79].  As reported in figure 12c three 
different culture conditions (isolated in FBS or PL; isolated in FBS and stimulated with PL for 30 
minute), at low (20%) and high (90%) confluences were tested. The data showed that only cells 
isolated or stimulated with PL expressed the C-MYC1 protein independently from the confluence 
reached. 
 
It has been shown that C-MYC1 protein is expressed not only in cells that stop growth  due to the 
contact inhibition arising from confluence, but also in cells subjected to lack of the essential amino 
acid methionine [79]. Our proliferation experiments showed that all primary cultures treated with 
PL are able to proliferate even for prolonged periods, without stopping their growth [4], as showed. 
by immunofluorescence for Ki67, a proliferation marker. Stimulation with PL for 24 hours showed 
expression of Ki67 (red spots in nuclei) as reported in Figure 13. This protein is a nuclear protein 
present in cells that are in interphase, but absent in the G0 phase of the cell cycle, which suggest 
that cells treated with PL are proliferating cells. So, cells expressing the C-MYC1 isoform, and 
therefore considered quiescent cells, were activated by PL treatment.  
 
Again to understand the role of C-MYC1 in the proliferation under PL conditions, by Vybrant® 
Apoptosis Assay Kit we evaluated if our cells, when treated with platelet derivatives, were 
apoptotic cells.  We applied this analysis on BMSC and ADAS cells, in the same condition 
described above.  
With this analysis we find that our cells, when treated with platelet derivatives, did not show an 
apoptotic profile, respect to the cells isolated in platelet derivatives and treated for 24 hours with 
FBS that are alive but show a low percentage of cells that are late apoptotic cells. For all the 
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treatment the cells appeared alive at the flow cytometry analysis showing a statistical difference 
from the death cells (Figure 14).  
Verified that PL treated cells, expressing the C-MYC1 isoform, did not show a proliferation 
stoppage due to reach of confluence, we went to search in literature what other causes were 
associated with the expression of the C-MYC1 isoform. 
 
C-MYC1 expression and the possible lack of methionine 
In literature was reported that this protein isoform is expressed from cells cultured in medium 
deprived of the essential amino acid methionine [79], a typical condition found in high confluence 
status. To understand the effect of PL in this condition, we evaluated the C-MYC1 expression in 
presence and absence of PL. The results reported in Figure 15, showed that the HeLa cells have also 
an increase in the C-MYC1 isoform after stimulation with PL, although apparently less marked than 
in primary cell cultures. We attribute these results to the weaker response of the cell lines to the 
treatment with PL respect to primary cell cultures [4]. Given the greater availability of HeLa cells, 
we used this cell line to test if the lack of methionine in culture medium could be responsible for the 
expression of the C-MYC1 isoform. This was evaluated in presence and absence of PL in an 
increasing gradual concentration of methionine in the medium (30-120 mg/L).  As shown in Figure 
16a, the different concentrations of methionine, in the medium, did not lead to a change in the 
expression of protein isoforms compared to PL alone in the medium (30 mg/L). Increasing 
methionine concentration up to 5mM and 10mM, the limit of tolerance by the cells, any effect was 
evident (Figure 16b).  
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DISCUSSION 
 
Most of the studies done so far with in vitro–expanded human MSC for therapeutic purposes used, 
as the main cell culture medium supplement was the fetal bovine serum (FBS or FCS). However, in 
this case, the use of FBS or FCS as medium supplements is undesirable because of the risk of 
transmitting animal viruses, prion diseases, including the bovine spongiform encephalopathy (BSE) 
in cows, and proteins that may trigger a xenogeneic immune response. The use of a human 
autologous serum avoids the zoonotic infection risk, but generation of autologous serum has 
significant limitations from a manufacturing, regulatory, and quality assurance perspective. Indeed, 
the large variability observed with sera from different patients deters their use for expansion of cells 
intended for therapy. Moreover, it is expected that the supply of bovine serum will be highly 
diminished in the near future years and that research and cell factory labs will be forced to modify 
their cell culture protocols and to adopt substitutes of FBS. For these reasons, human blood platelet 
lysate supplements are gaining an increasing interest as bovine serum substitutes, especially when 
cells that eventually will be implanted in a patient are cultured. 
 
Different procedures and protocols have been adopted for the preparation of these platelet lysate 
supplements [87] reviewed in [8,88]. In essentially all published protocols, including the recently 
published one of ours for the production of a two component supplement [4], the final human 
platelet derived additive included, in addition to growth factors and active molecules present within 
platelets, also a significant amount of proteins and other molecules component of plasma. To avoid 
coagulation of the plasma fibrinogen upon addition of the supplement to the culture medium, 
heparin is normally added as an anticoagulant agent. However, as already mentioned in the 
introduction, it has been reported by several authors that heparin is capable of interfering with the 
activity of several growth factors. Hemeda et al. have described that higher heparin concentrations 
impaired cellular proliferation in a dose-dependent manner [44]. At high heparin concentrations 
colony-forming unit frequency and the in vitro differentiation toward adipogenic and osteogenic 
lineages of human BM-MSC were also reduced. Moreover, being of animal origin, the addition of 
heparin should be discouraged whatever possible, especially when the culture medium is adopted 
for the expansion of cells intended for cell therapy.  
 
Compared to plasma, proteins and factors involved in the coagulation process are missing in the 
serum. Conflicting results have been reported on the use of allogenic serum, obtained by 
conventional blood coagulation or by coagulation of plasma, as culture medium supplement. Initial 
studies performed more than 10 years ago with human serum, revealed the possibility of efficiently 
isolate and expand human BM-MSC that maintained their differentiation potential [51]. Shetty et al. 
observed an increase of cell proliferation when human BM-MSC cultures were performed in the 
presence of human serum from whole blood compared to FCS [54]. In the presence of human 
serum. an enhancement in the adipogenic differentiation of the same cells was observed by Oreffo 
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et al. [89]. Enhancement of MSC differentiation induced by allogenic human serum or autologous 
plasma was observed also by other authors [56,57]. However, Shahdadfar reported an increased 
proliferation of human BM-MSC induced by autologous serum compared to FCS, but not by 
allogenic serum [59]. An increase in the proliferation, but a less effective differentiation of human 
pre-adipocytes was observed by Koellensperger et al [90]. Simões et al. observed an increase in the 
cell yield when MSC of different origins were cultured with human serum compared to FCS as 
medium supplement throughout passage 3 to passage 7 [91]. Recently a comparable UC-MSC 
proliferation was shown in cultures with human serum from two different plasma sources as 
medium supplement, plasma removed from blood after 24 h from collection and plasma devoid of 
cryoprecipitate [63]. However, in most, if not all, of the above cited papers and similar ones in the 
literature, a careful determination of the platelet factor concentration in the serum was not done and 
the adopted protocols not always guaranty the absence of platelets or platelet content as serum 
contaminants. 
 
Here we reported the development of two standardized lyophilized cell culture medium 
supplements: a completely plasma-free platelet lysate (v-PL) obtained from extensively washed 
platelets and a platelet lysate-free serum (Pl-s) obtained by a plasma cryo-precipitation, to remove 
the bulk of the fibrinogen molecules, followed by a calcium-mediated coagulation, to remove the 
residual fibrinogen. Characterization of these two products and investigation on their biological 
activity when used as cell culture supplements lead us to conclude that v-PL recruited quiescent, 
and even differentiated or senescent cells back to the cell cycle by activating the cell proliferation 
machinery (ERK and AKT phosphorylation, Cycline D1 induction, etc.). Instead, v-PL was unable 
to support cell proliferation unless the plasma or serum components were also present. These 
observations are in agreement with the interesting results obtained with primary cultures of monkey 
arterial smooth muscle cells [65]  and Swiss mouse 3T3 cells, embryo derived cells with a high 
degree of sensitivity to contact inhibition of growth [92,93], both types of cells requiring platelet 
derived growth factors in association to plasma components to sustain the cell growth, where 
platelet factors alone did not promote proliferation. Indeed, despite the fact that platelet derived 
mitogens were crucial to promote the reentry in the cell cycle (commitment) of confluent cells of 
early passages and even senescent cells of late passages of primary cultures, v-PL used as single 
component did not sustain viability and proliferation of either cell lines or primary cell cultures. On 
the contrary Pl-s was ineffective in quiescent resting cells, but supported proliferation of the same 
cells after v-PL treatment and of cells constitutively stimulated as in the case of established cell 
lines. In agreement with these findings, the combination of the two components was highly 
effective in supporting proliferation of primary cell cultures at a higher level than FBS in control 
cultures, whereas, the Pl-s added to the medium as a single component sustained the growth of 
several human cell lines in adhesion or in suspension at a growth rate comparable to the one of FBS 
control cultures. These results are in line with previous studies, dated back to almost forty years, 
where virally transformed cells grew well in plasma derived serum without the need of exogenous 
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platelet extract whereas malignant cells of mesodermal origin directly derived from tumors showed 
a range of dependence on platelet derived factors [94]. 
 
When we determined the efficiency of Pl-s and the plasma from which it was derived with regard to 
the ability to sustain cell proliferation in cultures of both primary cells and cell lines, we observed a 
comparable activity in the two medium supplements. However, a slight proliferation advantage was 
observed in cultures supplemented with the Pl-s. This was especially true for cells growing adherent 
to the Petri dish compared to cells growing in suspension. This finding suggests that, during the 
coagulation process, an activation of proteins and factors favoring adherence of proliferating cells is 
occurring, possibly through enzymatic proteolysis. 
 
The use of the two combined products allowed to establish cell cultures from tissue biopsies or 
aspirates in complete absence of animal components and to in vitro expand different types of cells, 
intended for cell therapy in humans, maintaining their differentiation potential and without 
introducing karyotype alterations. These cells include, but are not limited, to MSC derived from 
bone marrow, adipose or cord blood and articular chondrocytes. To note is that this, not only could 
consent to perform cell therapies with cells expanded in a safer condition (absence of animal 
components in the medium), but, in some cases, could allow to isolate and expand transplantable 
cells otherwise not achievable with conventional culture medium supplements. This is particularly 
relevant in case of elderly patients from which conventional culture medium supplements often do 
not permit to obtain an adequate number of cells. 
 
The C-MYC protein is involved in different cellular roles like cellular proliferation, cell size, 
differentiation, stem cell self-renewal and apoptosis [74]. In the last 30 years many investigations 
were made about this protein. C-MYC is implicated in different and critical biological roles at 
molecular level but its total implications are not clearly identified [85]. In particular, the protein is 
involved in several cellular pathways, interacting with different cofactors, and regulating the 
expression of different genes. In 1984 Hann S.R et al. [76], identified two protein of 64 and 67 kD 
as the major products of the C-MYC oncogene. These two different proteins have different exons 
where they initiate. C-MYC2 initiates from the first AUG site codon in C-MYC exon2, whereas C-
MYC1 initiates from a non-canonical site, indeed it starts from a CUG codon located near the 3’ 
end of exon 1 and differ from C-MYC2 by 14 or 15 N-terminal amino acids [75]. In 1992 it was 
demonstrated how C-MYC 1 appears to be specific for growth inhibition mediated by methionine 
deprivation, as a consequence of a physiological stress, because the deprivation of other amino 
acids did not cause its expression. Indeed, C-MYC2 is expressed during the cell cycle when the 
cells do not show any sufferings. In our work a strong activation of the C-MYC1 isoform is showed 
in primary cells culture under the stimulation or the isolation of the cells in PL (Platelet Lysate) but 
not when the cells are expanded in the control condition (10% FBS), whereas the cell line have a 
different behaviour, showing a lower constitutional expression of C-MYC1 isoform that is 
modulated under the stimulation or expansion with PL but without statistical differences respect to 
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the control condition. Considering the data of the literature [4,72], PL have different effect on the 
proliferation of cell line respect to primary cells cultures and activates some genes involved in cells 
proliferation like ERK, AKT and Cyclin D1 in osteoblast primary cells culture. In fact, the PL 
addition to cell line cultures allows to maintain growth rate standards similar to the control 
condition, instead for primary cell culture, the effect of PL is statistical better than the FBS 
expansion. 
Primary cells cultures stimulated with PL showed a double band in correspondence of C-MYC 
protein after 5 minutes, instead this double band was absent in cells that were in the standard 
condition.  
The second band had was nearly the first one, because the C-MYC1 protein differ from the second 
isoform (C-MYC2) only for few basis, indeed the two protein have a molecular weight of 64 and 67 
kD respectively. The presence of C-MYC1 band was also observed in other primary cells cultures 
like AFS (Amniotic Fluid Stem cells), hAC (human Articular Chondrocyte) and hOB (human 
OsteoBlast).  
As demonstrated from Hann S.R et al. [79] the expression of C-MYC1 protein was associated to 
high confluence reached by cells that lead to a deficiency of methionine in the medium. 
Our results performed in osteoblast at different confluence (high with 90% of confluence and low 
with 20% of confluence) showed how in presence of PL the C-MYC1 isoform was expressed 
independently from the confluence reached by the cells. This experiments showed that the 
confluence of the cells was not the cause of C-MYC1 expression, because the expression of this 
isoform was present also in cells that were in contact with PL even just for 30’ independently from 
the confluence reached.  
For the cell line, the result showed a scene slightly different because for this type of cells we 
obtained a modest expression of this isoform also in the standard condition (FBS). 
Some experiments were performed to show that the cells that express the C-MYC1 isoform are not 
growth arrested cells. Indeed, from previous observations [4], we know that cells grown in PL are 
proliferating cells. In this work the data demonstrate that the expression of C-MYC1 isoform was 
not associated with cells cycle arrest, on the contrary they resulted positive for Ki67 staining. Ki67 
is a typical nuclear marker associated with cellular proliferation. Experiments with Vybrant® 
Apoptosis Assay Kit revealed that these cells were not apoptotic. 
Experiments were carried out to show that the presence of PL in the medium was not responsible 
for the “sequestration” of the methionine in the medium. With these analyses the expression of the 
C-MYC1 isoform was observed also when the methionine concentration in the medium was at the 
higher level tolerable by cells leading to the result that the expression of that particular isoform was 
not due to the lack of methionine in the medium. 
All these experiments showed that PL was responsible for the induction or increasing of C-MYC1 
isoform in primary cells culture and much more slightly in the cell line. Surely this not sufficient to 
explain all the molecular mechanism that are at the base of the different response of the two types 
of cells to PL stimulation, but it paves the way to a deeper molecular study in order to understand 
peculiar differences of PL stimulation on various types of cells. 
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Role of C-MYC in the proliferation stage of mesenchymal stem cells cultured and selected by 
platelet derivatives  
Nardini M., Gentili C., Cancedda R., Castagnola P.,Mastrogiacomo M.  
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TABLES 
 
Table I).     Concentrations of PDGF-BB and VEGF in the culture medium supplements  
 
Sample PDGF-BB ng/ml ° 
(mean ± st dev) 
VEGF ng/ml * 
(mean ± st dev) 
 
Plasma-Serum  (Pl-s) 0.11 ± 0.06 0.02 ± 0.01 
virgin-Platelet Lysate (v-PL) 64.58 ± 9.10 4.35 ± 1.23 
 
° Average of 4 different preparations;  * Average of 2 different preparations  
 
 
Table II).     Karyotype stability in cells expanded in the presence of the new culture medium 
supplements  
 
 
donor age (years) passage doublings karyotype 
#1 73 2 10 46, XY 
#1 73 7 15 46, XY 
#2 94 2 11 46, XX 
#3 51 2 14 46, XX 
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FIGURES 
 
 
 
Figure 1: Manufacturing process outline: Steps in this procedure occur within a sterile closed system thanks to 
the possibility of performing sterile connections between blood bags. 
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Figure 2: v-PL effect on cell proliferation – primary cultures: Adult tissue derived primary cells, AD-MSC and 
BM-MSC or fetal tissue derived cells, UC-MSC initially selected and expanded in medium supplemented with 
10% FCS were transferred to media with different platelet and plasma derived supplements. Their proliferation 
rate was monitored by calculating the number of doublings performed during the time in culture. 
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Figure 3: v-PL effect on cell proliferation – cell lines: The human cell lines U937, HeLa, HaCaT and the hamster 
V79 cell line were cultured in the presence of different platelet and plasma derived supplements and their 
proliferation rate was monitored by calculating the number of doublings performed at different culture times. On 
the contrary to the behaviour of the primary cell cultures, cell lines are less responsive to the v-PL mitogenic 
stimulus and the culture condition in the presence of only serum, is permissive to the proliferation of the cells both 
in adhesion or in suspension. 
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Figure 4: v-PL promotes re-entry in the cell cycle of confluent resting cells: Upper panel: Confluent growth-
arrested chondrocytes, obtained from cartilage biopsies and expanded in vitro in the presence of 10% FCS, were 
maintained in 10% serum or additionally supplemented with 5% v-PL. A crystal violet proliferation assay was 
performed in parallel on both cultures. Confluent cells treated with v-PL resumed proliferation whereas the 
parallel control culture did not. Lower panel: Western blot analysis of proteins extracted from the cells treated 
with 5% PL probed with Cyclin D1, phospho Akt, phospho Erk1/2 and Actin antibodies shows that proliferation 
pathways were activated by v-PL also in the absence of serum. 
 
                                        
Figure 5: v-PL can rejuvenate a culture of senescent MSC: A culture of BM-MSC previously expanded in the 
presence of 10% FCS for about 10 population doublings was split in the different culture conditions. After 3 
weeks, one part of the cells of the culture in 10% Pl-s + 1% v-PL was transferred in medium supplemented with 
Pl-s without v-PL. After additional passages, at a time that proliferation was arrested (senescent cells), part of the 
Pl-s culture was transferred again in medium supplemented with 10% Pl-s + 1% v-PL (restoring in this way the v-
PL mitogenic stimulus). As shown by the graph, 1% v-PL cannot support cell proliferation, but the addition of v-
PL to senescent cells, maintained in the presence of Pl-s as the only supplement, rejuvenate the cells that resume 
proliferation. 
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Figure 6: Comparison of Pl-s and plasma as medium supplements Human primary cells (BM-MSC) and human 
cell lines growing either in adhesion (HeLa) or in suspension (U-937) were cultured either with Pl-s or plasma as 
medium supplements. Cell proliferation was determined by direct cell counting. 
 
 
Figure 7: Growth rate of cells cultured with the new supplements: The combined effect of Pl-s and v-PL on cell 
growth was tested on primary cultures of AD-MSC and compared to the control condition where cells were grown 
with the standard supplement FCS. The proliferation rate was monitored through the evaluation of the cumulative 
population doublings performed by the parallel cultures. 
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Figure 8: Maintenance of the differentiation potential by cells cultured in the presence of v-PL and Pl-s: Panel A-
B) Primary cultures of BM-MSC (passage 2); Panel C-D) Primary cultures of AD-MSC (passage 2); Panel B,D) 
Cells osteogenically induced for 3 weeks; Panels A, C) Not osteogenically induced control cells; Panel E-F) 
Human articular chondrocytes cultured as adherent dedifferentiated cells (Panel E) and transferred to suspension 
cultures (panel F) stained with antibodies against αII collagen. 
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Figure 9: Representative Karyotype of a passage 2 BM-MSC culture: Analyses of more than 10 metaphases 
revealed a normal 46 XX karyotype. 
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Figure 10: PL activates AKT and ERKs pathways. Sub-confluent cells were treated with PL and collected at 
different times starting at 5 min. Western blot analysis of cell lysates probed for ERKs (a) and AKT (b) and their 
phosphorylated forms. Tubulin was blotted as an loading control.  
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Figure 11: PL activates c-Myc1 isoform. Sub-confluent cells were subjected to different treatments and collected 
at different times starting at 5 min. Western blot analysis of cell lysates BMSC (a) and ADAS (b). Tubulin was 
blotted as an internal control. 
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Figure 12: PL activates c-Myc1 isoform. Sub-confluent cells were treated with PL for multiple time intervals 
starting at 5 min. Western blot analysis of cell lysates AFS (a), hAC (b) and hOB (c). Tubulin was blotted as an 
internal control. 
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Figure 13: Immunofluorescent analysis to evaluate the expression of Ki67 protein in cells treated with PL at 
different time. In Red fluorescence corresponds to positivity for Ki67 nuclear marker; while blue fluorescence 
corresponds to the nuclei of the cells (DAPI); merge represent the union of the two dyes. 
 
  
Figure 14: PL effect on the vitality of cells. Vybrant® Apoptosis Assay Kit with flow cytometry analysis was 
perform to evaluate if PL treatments induced apoptosis. 
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Figure 15: PL activates C-MYC1 isoform also in HeLa cells. Sub-confluent cells were treated with PL for 
multiple time intervals starting at 5 min. Western blot analysis of cell lysates was performed. Tubulin was blotted 
as an internal control. 
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Figure 16: Activation of C-MYC1 isoform in presence of PL and methionine stimulation. Sub-confluent HeLa 
cells were treated with PL for multiple time intervals starting at 5 min. Western blot analysis was perform on cell 
lysate of cells treated with PL and different methionine concentration: 30-120 mg/L (a) and 5-10 mM (b). Tubulin 
was blotted as an internal control. 
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2. ELECTROSPUN SILK FIBROIN FIBERS FOR STORAGE AND 
CONTROLLED RELEASE OF HUMAN PLATELET LYSATE 
 
ABSTRACT 
Human platelet lysate (hPL) is a pool of growth factors and cytokines able to induce regeneration of 
different tissues. Despite its good potentiality as therapeutic tool for regenerative medicine 
applications, hPL has been only moderately exploited in this field. A more widespread use has been 
limited because of its rapid degradation at room temperature that decreases its functionality. 
Another limiting factor for its extensive use is the difficulty of handling the hPL gels. In this work, 
silk fibroin-based patches were developed to address several points: improving the handling of hPL, 
enabling its delivery in a controlled manner and facilitating its storage by creating a device ready to 
use with expanded shelf life. Patches of fibroin loaded with hPL were synthesized by 
electrospinning to take advantage of the fibrous morphology. The release kinetics of the material 
were characterized and tuned through the control of fibroin crystallinity. Cell viability assays 
performed in primary human dermal fibroblasts demonstrated that fibroin is able to preserve the 
hPL biological activity and prolong its shelf-life. The strategy of storing and preserving small active 
molecules within a naturally-derived, protein-based fibrous scaffold was successfully implemented, 
leading to the design of a biocompatible device, which can potentially simplify the storage and the 
application of the hPL on human patients, undergoing medical procedures such as surgery and 
wound care. 
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INTRODUCTION  
Silk fibroin, a structural protein of the cocoons of the Bombyx mori, is widely studied for 
biomedical applications, such as tissue regeneration and drug delivery, because it is biocompatible, 
resorbable and can be fabricated in multiple formats [95–97]. The extraction of fibroin from the 
cocoons, a process known as regeneration, results in an aqueous solution that can be used to 
fabricate films, hydrogels, sponges, nanoparticles and fibers [95–102]. Silk fibroin self-assembles 
from the water solution into an amorphous state (called silk I) presenting α-helices, and a crystalline 
state (called silk II) with high β-sheets content [96,103,104]. The β-sheets characterizing silk II 
determine several of its physical and chemical properties, such as mechanical strength and 
refractive index [105,106].  Particularly interesting is the water stability provided by the β-sheet 
secondary structure: while silk I is soluble in water, highly crystalline silk II does not dissolve in 
pure water [107]. The transition from the amorphous state silk I to the crystalline silk II can be 
favored by using alcohols or via water vapor annealing [107–109]. The crystallization assisted by 
water vapor is slower, more controlled and it allows to obtain different crystallinity degrees by 
varying the treatment duration. Being a milder process, water vapor annealing can be applied even 
when sensitive molecules or cellular organelles are embedded in fibroin matrices [107,110–113]. 
Crystallinity manipulation of fibroin was used as a processing strategy to tune its biodegradability 
and to control the release of drugs. In vitro enzymatic degradation assays performed on fibroin 
fibrous scaffolds have shown a slower degradation rate when the scaffold presented high 
crystallinity [102,114,115]. In vivo studies confirmed the longer permanence of highly crystalline 
silk fibroin implants [116]. The control on the degradation is especially interesting in drug delivery 
applications, since controlling the rate of degradation enables the prolonged and sustained delivery 
of active factors during the entire course of the therapy. Investigations in vitro with highly 
crystalline silk fibroin matrices (>40% crystallinity) showed a slower release compared to the 
amorphous silk [117–121]. The ability of the silk fibroin in controlling the drug release was found 
also in vivo using chemotherapeutic agents, which were released in a sustained way and this kept 
their concentration under the toxic threshold [113,122]. Importantly, such controlled delivery can 
keep the overall drug concentration low within the patient’s body, reducing the frequency of the 
treatment administration [123]. Within the context of regenerative medicine, the sustained release 
of growth factors from biodegradable polymeric matrices showed accelerated and improved wound 
healing and great potential for more complete cells differentiation in tissue engineering [124–126]. 
Also for chronic wounds, keeping the concentration of growth factors low and the release for longer 
time, can help their healing [127,128].     
Human platelets lysate (hPL) is a potential therapeutic tool highly enriched with platelets-derived 
growth factors and cytokines. Although there are no publications reporting the exact and total 
content of single components of the hPL, many articles have described some of the growth factors 
included: platelet-derived growth factor B (PDGF-BB), fibroblasts growth factors (FGF), vascular 
endothelial growth factor (VEGF), epidermal growth factors (EGF) and transforming growth factor- 
β (TGF-β) [3,4,129]. Such growth factors are physiologically involved in regenerative and healing 
		48	
processes. In vitro experiments have shown the hPL ability to support every stage of the wound 
healing, favoring cells growth, angiogenesis and stimulating the recruitment of white blood cells 
[18,130,131]. In vivo experiments showed its ability to support bone regeneration and the recovery 
of non-healing wounds [132,133]. hPL is commonly applied in the form of a gel, which can release 
the platelets-derived factors [15]. Despite these promising results, on-the-spot preparation, difficult 
handling and the need of storage at low temperature to preserve the activity of the factors are some 
of the technical and practical limitations that still hinder the hPL usage as therapeutic tool 
[134,135]. Therefore, there is a need of designing a device that could conjugate the sustained 
release of the allogenic hPL with an easier handling on a wound, while keeping the hPL factors 
well-preserved. This would allow a more effective use of the hPL molecules in the wound care 
management. 
Herein, the hPL was encapsulated in silk fibroin electrospun fibers to exploit its tunable 
degradability and protective effect on sensitive molecules [111,136–142]. The electrospun format 
was chosen because the porosity granted by the micro and nanofibers facilitates both the absorption 
of exudate and an efficient gas exchange, while supporting cell proliferation and migration. All the 
above mentioned features successfully mimic the natural extracellular matrix, thus improving and 
sustaining the healing process of the wounds [143–146].  
Silk fibroin fibers with a high content of hPL were fabricated, and their degradation and release 
kinetics were controlled via manipulation of the fibroin crystallinity. The release kinetics of the silk 
fibroin fibrous mats with different crystallinity degrees were characterized tracking the release of 
albumin [147,148] using an in vitro test that was developed to simulate in vivo degradation 
conditions. hPL released from silk fibroin fibers retained its ability to induce and sustain the 
viability of primary adult human dermal fibroblasts (HDFa) in vitro. Finally, the possibility to use 
silk fibroin for the preservation of hPL biological activity was proved even after thermal stress at 60 
°C [140,142], demonstrating the improvement of the shelf-life of hPL, granted by the fibroin 
matrix. Such construct can be proposed as a valid, easy-to-fabricate and durable alternative to the 
platelet-rich plasma (PRP) gel in the wound care management. 
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MATERIALS AND METHODS 
 
Materials 
Sodium carbonate, sodium chloride, lithium bromide, poly (ethylene oxide) (PEO, Mw=1,000,000 
g/mol), albumin conjugated with fluorescein isothiocyanate (FITC-albumin), phosphate buffer 
saline (PBS), Protease XIV (≥4 units/mg), paraformaldehyde (PFA), and bovine serum albumin 
(BSA) and Triton X-100 were purchased from Sigma Aldrich (MO, USA). Human dermal 
fibroblast from adult (HDFa), medium 106, low serum growth supplement kit, trypsin, trypsin 
neutralizer, Alexa Fluor™ 488 Phalloidin and ProLong™ Diamond Antifade Mountant with DAPI 
were purchased from ThermoFisher Scientific (MA, USA). Cell proliferation reagent WST-1 (2-(4-
iodophenyl)-3-(4-nitophenyl)-5-(2,4-disulfophenyl)-2 H-tetrazolium monosodium salt) was 
purchased from Roche (Switzerland). Finally, hPL was gently granted by Bioregen s.r.l. (Italy). 
 
Fibroin regeneration and hPL preparation 
Fibroin was extracted from Bombyx mori cocoons according to the protocol previously described by 
Rockwood et al. [97]. Firstly, the cocoons were cut and boiled for 30 minutes in a water solution of 
0.023M of Na2CO3; subsequently, the fibers were washed with MilliQ (18.3 MΩ) water and dried. 
Degummed fibroin, was solubilized in an aqueous solution of 9.3 M of lithium bromide at 60°C for 
4 hours and dialyzed in a tube with a MWCO of 3500 kDa for 3 days against MilliQ water. Finally, 
regenerated fibroin was centrifuged twice at 9000 rpm, for 20 minutes at 4 °C. To quantify the 
fibroin concentration, 1 mL of regenerated fibroin solution was left to dry under an aspirating hood. 
Then, the dried film was weighted, obtaining the concentration of silk fibroin in the solution. The 
concentration was found to be in a range between 60 and 80 mg/mL.  
hPL used in this work, provided by Bioregen s.r.l., was prepared according to the method described 
by Zaky et al. [3]. Briefly, PRP obtained from buffy coat samples from the whole blood of healthy 
donors was subjected to several freeze-thaw cycles in order to break the platelet membranes and to 
release their growth factors content. The supernatant hPL recovered was freeze-dried. It contained 
platelet growth factors with different size. To reduce or avoid the variability from batch to batch, 
each single batch was derived from 400 donors. hPL was standardized among batches by making 
sure PDGF-BB and VEGF concentrations were constant [4,129]. 
 
Fibers fabrication and water vapor treatment 
To produce the fibers, a fibroin 60 mg/mL solution was used. To facilitate the electrospinning 
process and fabricate the fibers, PEO powder 25% (w/wsilk) was added to a 60 mg/mL aqueous 
solution of fibroin and stirred overnight. Generally, to electrospin silk fibroin, PEO is added 
because it adjusts the viscosity of the regenerate silk fibroin, as reported in previous works [149–
152]. Once a homogeneous solution was obtained, FITC-albumin powder was added such to obtain 
a concentration of 2% (w/wsilk). To add hPL, a solution of it 7% (w/wsilk) was added to not diluted 
silk fibroin solution. Therefore, hPL solution needs to have an enough volume to dilute the silk 
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fibroin solution at 60mg/mL. The final concentration of the hPL in the electrospun fibers was 5% 
(w/w). The fibers were electrospun at 20°C in a controlled humidity environment (30% - 40% 
relative humidity) with a syringe pump (NE-1000, New Era Pump Systems, Inc., NY, USA) 
equipped with a blunt 19G needle, at a flow rate of 1 mL/h (Figure S1a). An aluminum, grounded 
collector was placed at 20cm from the needle, while a voltage of 18 kV was applied (EH40R2.5, 
Glassman High Voltage, Inc., US-NJ, USA). In the case of the hPL loaded fibers, the following 
parameters were set: a flow rate of 1.2 mL/h, a needle - collector distance of 30 cm, and a voltage of 
23 kV. These parameters were optimized for the different compositions in order to have a 
continuous electrospinning process and to produce beads-free fibers. 
The crystallinity degree of the silk fibroin fibrous mats was increased via water vapor annealing. 
The treatment was performed in a vacuum oven (VO500EA, MLS, Italy) at 40°C and 85-90% of 
relative humidity. Different treatment times were used for the different crystallization reported 
(Figure S1b), ranging from 10 minutes to 6 hours. 
 
Fiber characterization  
Morphology 
Fiber morphology was characterized by scanning electron microscopy (SEM) using a JEOL JSM-
6490LA microscope (JEOL Ltd., Japan) in high vacuum with an acceleration voltage of 15kV. The 
samples were previously coated with a 10-nm-thick gold layer with a Cressington 208HR high 
resolution sputter coater (Cressington Scientific Instrument Ltd, U.K.). Size analysis was performed 
with ImageJ software (NIH, USA). To evaluate the encapsulation of the FITC-albumin molecules, 
confocal imaging was performed with a laser scanning confocal microscope (A1R, Nikon, Japan). 
The lasers had wavelengths of 401 and 488 nm (Nikon, Japan). 
 
Fibroin crystallinity characterization 
Characterization of the fiber crystallinity was performed by Fourier transform infrared spectroscopy 
(FTIR). Samples were measured in Attenuated Total Reflectance (ATR) mode using MIRacle ATR 
accessory (PIKE Technologies, WI, USA) coupled to a Fourier Transform Infrared (FTIR) 
spectrometer (Equinox 70 FT-IR, Bruker, MA, USA). All the spectra were acquired in a spectral 
range from 4000 to 600 cm-1, with a scanning resolution of 4 cm-1, accumulating 64 scans.  
The deconvolution of the fibroin amide I peak was performed as reported previously by Guzman-
Puyol et al. and Hu et al. [153,154]. The software was PeakFit 4.11 [153] and the wavenumber 
positions of the different components were deduced by calculation of the second-order derivative 
[154]. The fitting of the different contributions was performed using Gaussian-shaped peaks, using 
a fixed width for each considered peak. The crystallinity content was obtained from the ratio 
between the areas of the β-sheets peaks and the total area of the amide I peak. 
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Drug release assessment and degradation of Electrospun silk fibroin 
Electrospun silk fibroin unloaded (SF), loaded with FITC-albumin (SF-alb), loaded with hPL (SF-
hPL) and loaded both with FITC-albumin and hPL (SF-alb-hPL) fibers, were weighted and placed 
in a 24 well-plate with 1 mL of PBS 0.04M at pH 7.4 and with 6.25 mU of Protease XIV in 0.04M 
PBS pH 7.4 at 37°C and gently stirred on a tilting plate for 5 months. At given time points, the total 
volume was taken out and substituted with fresh medium. The amount of FITC-albumin was 
determined by correlating the absorbance at 495 nm with a calibration curve measured by using the 
same media, after subtraction of a blank spectra obtained by measuring the SF and SF-hPL samples. 
The measurements were carried out using a UV-visible spectrophotometer (Cary 6000i-Varian, CA, 
USA) from 450 nm to 550 nm.  
To characterize the effect of the enzymatic degradation on the samples, three SF-alb-hPL mats 
having different crystallinity (22%, 35% and 45%) were incubated at 37 °C for 1 month, either with 
PBS or in the presence of PBS containing the enzyme (6.25U/mgfibers). The medium was completely 
replaced every day. Subsequently, the mats were washed with MilliQ water for 10 minutes five 
times, in order to remove traces of salt and enzyme. After the final timepoint, the samples were 
rinsed, dried and imaged by SEM. 
 
Biological activity of the released hPL 
Primary human dermal fibroblasts from an adult donor (HDFa) were seeded in medium 106, 
containing 2% v/v of fetal bovine serum (FBS), 1 μg/mL of hydrocortisone, 10 ng/mL human 
epidermal growth factor (hEGF), 3 ng/mL of basic fibroblast growth factor (bFGF), and 10 μg/mL 
of heparin. The cells were split every 7 days and seeded at a density of 4500 cells/cm2 and grown at 
37 °C in 5% CO2 atmosphere. Medium was changed every day.  
To assess the retained activity of the released hPL, 20 mg of SF and SF-hPL fibers, at 24% of 
crystallinity, were sterilized with UV treatment for 20 minutes for each side and incubated in 4 mL 
of serum-free culture medium for 24h at 37°C. The low crystallinity of the mats permits the 
dissolution of the matrix and the complete release of all the factors in 24h hours. The size of silk 
fibroin mats dissolved in the serum-free culture medium, was cut in order to release 250 µg/mL of 
hPL in the media. This concentration was chosen because, as observed in a dose-response 
experiment (Figure S5), it was found to be the minimum concentration able to increase the viability 
of the HDFa. Twenty-four hours before the treatment, cells were seeded at a density of 4500 
cells/cm2 in complete culture medium. The day after, some cells were used to assess the viability 
before the treatment with the samples. This reading was labeled time point zero. The rest were 
washed with PBS and incubated according to the following conditions: SF extract, SF-hPL extracts, 
culture media containing the same hPL amount released from the SF-hPL, and serum-free culture 
media and complete culture media as controls. Cells viability was evaluated through the analysis of 
the cell metabolism, thanks to a colorimetric assay. WST-1 was directly added in culture medium 
with a 1:11 (v/v) ratio. After the addition of the WST-1, the cells were incubated for 3 hours, at 
37°C with and 5% of CO2. The assay was performed after 1, 3, and 5 days of treatment, acquiring 
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the absorbance at 450 nm, through a multiwell plate reader (Multiskan™ GO Microplate 
Spectrophotometer, ThermoFisher scientific, MA, USA) and normalizing all the outcome signals 
with respect to the absorbance value at the zero-time point. 
 
Improvement of hPL shelf-life  
With the aim of mimicking a degradation process, an oven treatment at 60 °C was performed on SF 
and SF-hPL samples, lyophilized hPL and on aliquots of plain and hPL-containing serum-free 
culture media. Lyophilized hPL represents the common way for storage; hPL dissolved in serum-
free culture media mimics the common “device” use to deliver hPL: the platelet gel; SF-hPL is the 
ready-to-use silk fibroin-based device. 60 °C were used because it is a temperature at which labile 
molecules, like hPL, are known to degrade and because it is a temperature used in previous works 
to test the improvement of stability granted by silk fibroin [140,142]. The electrospun mats were 
cut-down to be 20 mg in mass, containing 1 mg of hPL each. After the oven treatment and 20 
minutes of UV sterilization cycle for each side, they were dissolved in 4 ml of serum free culture 
media for 24 h at 37 °C, to release the encapsulated hPL and prepare the extract for the following 
cell experiments. All the electrospun samples were 24% crystalline, so they fully dissolved during 
the 24 hours of incubation. For the control samples, lyophilized hPL was dissolved in the serum-
free medium in order to have the same concentration of the electrospun samples (250 µg/ml). Three 
treatment time points were investigated: 24 hours, 48 hours and 72 hours. HDFa cells were seeded 
onto 96-well plates at a density of 4500 cells/cm2 and let attached overnight. The next morning, 
cells were treated with the prepared extracts from the thermally treated samples above listed. WST-
1 viability assay was performed after 5 days, acquiring the absorbance at 450 nm and normalizing 
all the outcome signals with respect to the absorbance value of the negative control. The residual 
activity of the hPL was calculated from the ratio of the cell viability observed in the case of the 
thermally treated mats and the cell viability in the case of the untreated samples. 
 
Cell morphology  
To evaluate the morphology of the cells directly seeded onto the fibrous mats, electrospun silk 
fibroin fibers were collected on 14 mm coverslips and treated with water vapor, as previously 
described. After UV sterilization of the Electrospun silk fibroin fibers for 20 minutes, HDFa were 
seeded on SF and SF-hPL matrices and observed under the confocal microscope after 1, 3 and 5 
days of growth. Cells were washed twice with PBS, fixed with PFA 4% for 10 minutes and treated 
with Triton X-100 0.1% in PBS for additional 10 minutes. Afterwards, the samples were incubated 
with a blocking solution of 1% BSA in PBS for 20 minutes and then stained with Alexa Fluor™ 
488 Phalloidin (diluted 1:40 in 1% BSA) for 20 minutes. All the steps were performed at room 
temperature (RT). Finally, the cells were mounted on glass slides with ProLong™ Diamond 
Antifade Mountant containing DAPI for nuclear staining and stored at 4 °C. 
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Statistical analysis 
The analysis of the fibers size was performed on three samples for each fibrous formulation (SF, 
SF-alb, SF-hPL and SF-alb-hPL) before and after the water vapor annealing. The average of size 
measurements (n = 400) was obtained along the respective standard errors.  
Three samples of each fibrous sample and each condition (not treated, treated for 10 minutes and 
treated for 6 hours with water vapor) were used for FITR analysis, acquiring 5 spectra from each of 
them, which were averaged to obtain the final spectrum for the deconvolution. The same samples 
(three for each crystallinity degree and three for each fibers type) were used to investigate the 
release. The average of the release from the triplicates was obtained with the respective standard 
errors. The cell viability assays were repeated 3 times for each fibrous sample. The average with the 
respective standard error was obtained and statistical differences were assessed by the analysis of 
variance (ANOVA), followed by post-hoc Bonferroni correction. A value of p ≤ 0.05 was 
considered statistically significant. 
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RESULTS  
 
Fibers fabrication and characterization 
In Figure 1 and Figure S2 electrospun mats of silk fibroin fibers (SF), FITC-albumin loaded silk 
fibroin fibers (SF-alb), hPL-loaded fibers (SF-hPL) and silk fibroin fibers with both FITC-albumin 
and hPL (SF-alb-hPL) are presented. The fibers were defect-free, showing a smooth morphology. 
Their average diameter was measured to be 370±3 nm, 330±2 nm, 360±3 nm, and 480±2 nm, 
respectively. After the water vapor treatment was performed, no statistically significant change in 
the average diameter was observed, with dimensions of 400±4 nm, 370±3 nm, 480±4 nm, and 
530±8 nm, respectively. 
Although different electrospinning parameters were used, the size and the morphology of the fibers 
did not significantly change with the addition of the FITC-albumin or hPL. Up to 5% (w/w) of hPL 
can be loaded in the fibers because above this amount, the process became less continuous and 
reproducible.  
After the water vapor treatment, the surface of the single fibers resulted smooth, indicating that such 
treatment did not induce modifications on their surface. On the other hand, it induced the flattening 
of the fibers in all the formulations, an effect often associated with post treatment of fibroin fibers 
(Figure 1) [155,156]. 
FITC-albumin was used as a tracer to characterize the release kinetic of the hPL from the 
electrospun fibers, since albumin is one of the elements of hPL (Figure S2) [147,148]. The 
successful encapsulation was verified with a confocal microscope, through the FITC fluorescence 
determination (Figure 2). The distribution of the fluorescence signal appeared homogenous along 
the fibers and no differences were observed when the hPL was added to the system (Figure 2).  
Silk fibroin’s secondary structure (i.e. the formation of β–sheets domains) is important to tailor the 
release kinetics from the electrospun samples. To characterize it together with the modifications 
induced by water vapor annealing, the amide I peak was analyzed by FT-IR and reported in Figure 
3 [107]. The peak of the non-treated fibrous mats was centered at 1651 cm-1. After 10 minutes of 
water vapor treatment, the spectra showed a change in the peak shape, with a shoulder at 1628 cm-1, 
while a further shift to 1624 cm-1 was noticed after 6 hours treatment. These changes can be 
associated to an increase in the β-sheets formation, as reported previously by Hu et al. [154].  
The crystallinity degree was calculated for each sample through the deconvolution of the amide I 
peak. As expected, non-treated electrospun fibers showed a β-sheets content ranging from 21% to 
24%. On the other hand, fibers treated for 10 minutes presented a crystallinity degree of 34-36%, 
while those undergoing water vapor annealing for 6 hours reached up to 44-46% of crystalline 
phase.  
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Drug release assessment  
To precisely assess the release kinetics for all the crystallinities explored, a release medium with 
proteolytic enzymes was developed in order to simulate the in vivo enzymatic degradation. Protease 
XIV was used as proteolytic enzyme. Such protease is commonly used as enzyme for comparing 
the degradation properties of the silk fibroin [157,158]. The quantity of the protease was selected, 
after testing several concentrations, to ensure that the time of degradation of the fibroin in the 
release medium would has the same kinetics reported in literature for the biodegradation in vivo. To 
select the protease concentration, 6.25 mU/mgfibers and 250 mU/mgfibers were tested (Figure S3). The 
6.25 mU/mgfibers was chosen because it resulted in a degradation time of 10 months, comparable to 
previous data reported in literature on the silk fibroin biodegradation in vivo. [116,159] 
Figure 3 shows the release profiles of FITC-albumin from the fibrous mats, with different 
crystallinity, over a period of 5 months. The results are summarized in Table I. The study was 
performed on both SF-alb and SF-alb-hPL mats. In both cases, the fibers presenting the lowest 
crystallinity were totally dissolved within 1 hour and all the encapsulated FITC-albumin was 
completely released. During the initial burst, the samples with about 30% crystallinity released 
41±2% - 48±2% of the loaded FITC-albumin. A strikingly different behavior in this initial phase 
was observed for the samples with 45% of crystallinity, which released only 6±0.2% - 10±0.7% of 
the total loaded FITC-albumin. After the initial burst, the release continued with a slower rate for all 
the samples. For example, after 25 days SF-alb samples with 33% of crystallinity showed a release 
of 90±0.3%, while samples with crystallinity of 46% released 38±1% of the total FITC-albumin 
(Figure 3d). Similarly (Figure 3e), for the SF-alb-hPL samples, a release of 80±2 % was observed 
from the mats with 35% of crystallinity, while a release of 46±1% was observed from the 44% 
crystalline mats. As shown in Figure S3, this sustained phase of the release was absent in all the 
samples when the Protease XIV was not used during the experiment, and a plateau at the end of the 
burst was observed. 
In Figure 4, SEM images show the fibers morphology of SF-alb-hPL mats with different 
crystallinity incubated with and without the enzyme for 1 month. The morphology of the fibers 
without the enzyme was preserved, unlike those incubated with the enzyme, confirming the 
destructive activity of the Protease XIV towards the fibroin. The loss of the fibers’ morphology was 
higher when the crystallinity was low. The effect of slower degradation of silk fibroin by Protease 
XIV caused by the increased crystallinity was observed also by Gil et al. [158]. They attributed this 
effect to the slower diffusion of the enzyme in the amorphous fibroin phase. In fact, after its 
crystallization, supramolecular interactions in the amorphous silk fibroin increases, such to create a 
more organized structure, which retards the passage of the enzyme through the crystalline domains. 
The results in Figure 4 are in agreement with the model they proposed by them, confirming also 
that this crystalline dependent degradation drove the second phase of the release. 
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Biological activity of released hPL 
To verify the activity of the hPL encapsulated in the fibers, low crystalline SF and SF-hPL samples 
were incubated in serum-free culture media for 24h. The Protease XIV was not used, since the 
sample completely dissolved in the media thanks to their low crystallinity. Figure 6a shows the 
viability of HDFa cells treated with media containing the dissolved fibers. As control samples, cells 
were seeded in FBS-free media (labeled as negative control), in FBS-free media in which 
lyophilized hPL was dissolved at the same concentration (labeled hPL), or in media with FBS 
(labeled FBS). The amount of hPL in the control was the same as the one released from SF-hPL 
fibers (250 µg/mL). This concentration, from the results showed in Figure S5, resulted sufficient to 
observe an increase in HDFa viability. The absorbance values of all the days were normalized to the 
absorbance values relative to the zero-time point. After the first day of treatment, cells cultivated in 
media with hPL (hPL and SF-hPL samples) had the same increase in the viability (p>0.05) and 
showed a two-fold increase in the viability when compared to the negative control. This higher 
viability can be associated to the cell proliferation induced by the hPL, as reported before [160]. 
These trends were confirmed after 3 and 5 days. Silk fibroin produced no effects on the cells 
viability, confirming that the increase in this parameter was due the hPL released from the fibroin 
fibers. Therefore, these results proved that the growth factors released from the SF-hPL were still 
active and that they could increase and sustain cells viability of the HDFa cells for up to 5 days.  
 
Cell morphology 
To evaluate the role of the hPL in cell adhesion and morphology, HDFa were seeded on the SF and 
SF-hPL mats for 5 days. Intermediate crystalline fibrous mats (about 30% crystallinity) were used, 
in order to avoid their dissolution and allow the cells to attach. As showed in Figure 6b and c, the 
cells attached onto SF mats mostly showed a rounded morphology, while, when seeded onto SF-
hPL fibers the cells appeared more elongated. Moreover, the presence of the hPL in the fibers 
seemed to accelerate cellular adhesion processes. Control samples on flat films with the same 
composition of the SF-hPL fibers, shown in Figure S7, confirmed that the elongated morphology is 
caused by the hPL encapsulated in the fibers.   
 
hPL shelf-life 
To test if the activity of hPL growth factors can be preserved via encapsulation in silk fibroin fibers, 
an accelerated stability test was performed, inducing a thermal stress at 60 °C [140,142]. Three 
conditions were tested: lyophilized hPL, hPL dissolved in serum-free medium and SF-hPL. As 
shown in Figure 7, the activity of the free hPL in solution was reduced to 66±3% after 1 day of 
thermal treatment and it decreased to 41±2% after 3 days. The lyophilized hPL, showed an activity 
of 76±2% after 3 days of treatment. On the other hand, the activity of the hPL released from the SF-
hPL mats, thermally treated for 3 days, was 88±6%. It resulted statistically more active than the 
lyophilized hPL (p<0.05) and the dissolved hPL (p<0.0001), demonstrating the ability of silk 
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fibroin to preserve the functionality of the encapsulated molecules even at temperatures that are 
expected to denature the labile hPL components.  
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DISCUSSION 
Silk fibroin electrospun fibers, were fabricated from the aqueous solution of fibroin, using PEO to 
facilitate the process, following a strategy adopted in previous works [149–152]. This procedure 
proved to be effective even for high loading of hPL. To have well-formed submicron fibers, the 
parameters were adjusted to account for the presence of meta-stable, complex composition of hPL.  
Since albumin is a component of the hPL (as reported in literature and confirmed by us in Figure 
S2g), the fluorescently tagged FITC-albumin was encapsulated in the fibers and used as a tracker 
because of its easier detection [148]. The homogeneous encapsulation of FITC-albumin in SF-alb 
and SF-alb-hPL suggested a homogeneous loading of hPL in the electrospun mats as well. In 
addition, the confirmation of the hPL encapsulation was demonstrated with the in vitro experiments.  
Through the water vapor treatment, a fine control on the fibroin crystallinity was ensured, enabling 
the tuning of the release time of FITC-albumin from the electrospun samples (SF-alb and SF-alb-
hPL) over a large range of time scales. As suggested by previous works [117,118], in the release of 
FITC-albumin from the electrospun mats two different phases were distinguished: a first burst 
release, that might be relative to the dissolution of part of the fibers, with a quick diffusion, and a 
second slower and more sustained release that could involves the enzymatic degradation of the 
fibers, as observed in the SEM images in Figure 4. This hypothesis is supported by the experiments 
showed in Figure S3, where in the absence of a proteolytic enzyme, the release was inhibited after 
the first 24 hours.  
The degradation mechanism of silk fibroin depends on its crystallinity [157]. Thus, at low 
crystallinity (<20 %) a fast dissolution is the main pathway for degradation, while, when the 
crystalline phase is increased (>40 %), the main pathway accountable for the degradation is the 
proteolysis, being the dissolution is responsible only for 4% of the mass [114,116–118,157–
159,161]. Therefore, considering that the release of drugs from silk fibroin matrices is intertwined 
with the material’s integrity, for amorphous silk, the release is dictated by the dissolution of the 
material, while for silk with high β-sheets content the kinetic depends on the molecular weight of 
the drug. A schematic depicting these two mechanisms is reported in Figure 5. The outcomes 
reported in Figure 3 and Figure S4 suggested that, even for highly loaded samples (SF-alb-hPL), the 
release was mostly dictated by the fibroin matrix and its crystallinity degree. 
In a previous work by Hines and Kaplan [117,118], the release of small molecules from silk fibroin 
films was characterized. Two sequential steps were hypothesized: an initial release controlled by 
the diffusion of the molecules within the fibroin matrix, followed by a second step in which the 
release from the silk fibroin film was supposed to be controlled by the degradation of the polymeric 
matrix. The results of this study support our proposed model in which, after the initial burst, the 
degradation of the silk fibroin matrix plays an important role in determining the rate of release. We 
show here, for the first time, that this degradation-dependent release, hypothesized by Hines and 
Kaplan, is able to support a sustained release. When enzyme degradation is not present, the 
molecules would remain entrapped in the fibroin matrix, whereas, by adding Protease XIV, the 
demolition of the crystalline domain induces the release of the FITC-albumin.  
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Hines and Kaplan also demonstrated that the release kinetic of a drug depends on its molecular 
weight [117], while Nultsch and others [162] showed the effect of the molecules charge (or their 
isoelectric points, IP) on the release rate [163–166]. Thus, for hPL proteins with molecular weight 
and IP similar to albumin, the release kinetic during the burst phase (0 h to 24 h), the degradation 
phase (24 h to 7 days) and the sustained degradation (8 days to exhaustion) are reported in Table Ib. 
The rates have been obtained from the graph in Figure 3. These results showed how the release of 
drugs can be tuned from few hours for the low crystalline silk fibroin (< 24 % crystallinity), up to 
20 days for the intermediate crystalline samples (between 25 % and 35 % crystallinity), and a 
sustained release for up to 100 days for the highly crystalline silk fibroin (> 36% crystallinity). The 
main growth factors of hPL have molecular weight slightly lower than albumin (between 22 and 44 
kDa) and IP higher than albumin (8-9 and 4,7 in hPL growth factors and albumin, respectively). 
The lower molecular weight is expected to facilitate the diffusion, while the higher IP is expected to 
retard it, making the exact release of the growth factors difficult to predict. Nevertheless, since the 
crystallinity of silk fibroin provide a general mechanism to tune the kinetic of the release, growth 
factors wouldl be released slowly from highly crystalline silk fibroin than from low crystalline silk 
fibroin. Further studies are needed to precisely assess the release kinetic of the different components 
of hPL, because of the diversity of protein size and the possible formation of aggregates.  
Viability assays performed on the HDFa cells, reported in Figure 6, demonstrated that the labile 
growth factors and cytokines present in hPL are still active after all the fabrication steps. Moreover, 
HDFa cells seeded onto SF-hPL fibers were able to successfully attach on the matrix, acquiring an 
elongated morphology which was kept during all the 5 days of growth (Figure 6b, c and Figure S6). 
As shown by Barsotti et al. [130] and Anitua et al. [160], platelets-derived proteins induced similar 
changes on dermal fibroblast. This morphology was hypothesized to be associated to cell 
polarization, a complex process involved in cell migration and wound closure [18].  
The preservation of the hPL growth factors activity is of crucial importance not only in the short 
term of usage, when applied as wound management device, but also in the long term of storage after 
the fabrication. Nowadays, the general usage of the platelets-derived factors is in a gel form, which 
needs to be prepared immediately before the treatment [15]. This procedure is time consuming, 
difficult and only accessible to qualified operators. Thus, the possibility of having a hPL-
encapsulated device as a ready-to-use patch should simplify the operations. Given the meta-stability 
of the growth factors, an improved device should be able to protect and preserve the biological 
activity of the hPL proteins in the long term. Fibroin is known to be able to preserve growth factors 
and enzymes, and to stabilize blood [107,110–112,119,136–142,167]. As highlighted in Figure 7, 
hPL released from SF-hPL patches was able to increase cell viability after 3 days of thermal stress, 
demonstrating the protective role of the fibroin towards the hPL proteins. These results show that 
the SF-hPL device, in its ready-to-use form, has a stability that is even better than the lyophilized 
form of hPL. This entails the possibility that SF-hPL devices could be prepared in advance, 
simplifying their conservation and facilitating their use.  
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In summary we show here that hPL was successfully encapsulated with high loading efficiency into 
electrospun silk fibroin fibers up to 5% (w/w) of the total mass of the fibers. The release kinetics 
from the silk fibroin fibers, characterized using FITC-albumin, were shown to be tunable by 
controlling silk fibroin’s crystallinity using a simple and mild water vapor treatment. All the steps 
involved in the release dissolution of the matrix, diffusion rate and degradation of the fibers have 
been shown to be affected by the fibroin crystallinity, with samples with the highest crystallinity 
having the smaller dissolution and the slower diffusion and degradation.  
Encapsulated hPL retained its biological activity, sustaining the HDFa cell growth in vitro for up to 
5 days. Interestingly, hPL treated cells appeared to acquire a more polarized morphology, typical of 
migrating cells that are involved in the wound closure. Finally, the accelerated stability test revealed 
the maintained bioactivity of the growth factor pool, confirming silk fibroin’s ability of preserving 
sensible molecules. hPL in the fibroin patches has an extended shelf life and will not require 
particular storage conditions. The proposed engineered fibers could facilitate the use of hPL for 
wound healing and in medical procedures in which hPL gels are currently used. Electrospun patches 
are readily applicable to the wound site, similarly to a gauze, could have a pre-determined release 
kinetic and could be prepared and store as ready-to-use devices thanks to the preservation of the 
hPL activity and the prolonged shelf life granted by the silk matrix. 
A more precise knowledge of the growth factors’ releases and their biological activity in vitro and 
in vivo, could lead to the exploit of the facile usage, tunable degradation and sustained release in 
different applications from wound healing to regenerative medicine. 
 
 
This work is presented in the publication submitted to Acta Biomaterialia: 
 
Electrospun silk fibroin fibers for storage and controlled release of human platelet lysate 
Cataldo Pignatelli, Giovanni Perotto, Marta Nardini, Maddalena Mastrogiacomo, Ilker S. Bayer, 
Ranieri Cancedda and Athanassia Athanassiou  
  
		 61	
FIGURES	
          
               
Figure 1: SEM images of SF (a and b) and SF-hPL (d and e) fibers mats obtained by electrospinning. The fibers 
morphology is characterized before (a and d) and after (b and e) the water vapor treatment. The insets show the 
corresponding size distributions. Photos of the obtained electrospun SF (c) and SF-hPL (d) fibrous mats. 
 
             
Figure 2: Confocal microscope images of SF-alb (a, b and c), and SF-alb-hPL (d, e and f). 
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Figure 3: Deconvoluted FT-IR spectra of the amide I band of non-treated fibers (a), fibers treated for 10 minutes 
(b), and fibers treated for 6 hours (c). The crystallinity content for these samples are 21%, 34%, and 45%, 
respectively. SC = side chains; B = β-sheets; R = random coils; A = α-helices; T = turns.  
FITC-albumin release kinetics: (d) SF-alb and (e) SF-alb-hPL electrospun fibers. The percentages indicate the 
crystallinity of the fibrous mats. The release medium contained Protease XIV, to simulate the in-vivo degradation. 
 
                             
Figure 4: SEM images of SF-alb-hPL mats with different crystallinity. Micrographs a, b and c depict fiber 
morphology for the mats with crystallinity of 22%, 35% and 45% respectively, incubated in PBS for 1 month. 
Micrographs d, e and f, show the resulting morphology of mats at equal crystallinity after incubation with protease 
XIV (6.25mU/mgfibers). 
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Figure 5: Proposed mechanism of controlled release from silk fibroin fibrous mats, considering the different silk 
fibroin crystallinity degree and the presence of the enzymatic activity. Low crystalline samples completely 
dissolved during the burst release, while the highly crystalline samples featured a reduced release due to the 
presence of the crystalline domains which impaired the diffusion of the FITC-albumin molecules. After the burst 
release, for the highly crystalline mats, when the enzyme degradation is not present, the molecules would remain 
entrapped in the fibroin matrix, whereas, by adding an enzyme, the degradation of the crystalline domain induces 
the release of the FITC-albumin and the other molecules embedded in it. Therefore, crystallinity also appeared to 
affect this second release step, since the silk fibroin crystalline domains constitute a physical barrier that limits the 
accessibility of the cleavage sites, leading to a slower degradation rate of the fibers during the release process. 
This leads to a crystallinity-dependent release. 
 
 
 
Figure 6: a) Viability of HDFa cells treated either with 250 µg/mL of hPL or with the extracts of SF and SF-hPL 
fibers. The values were normalized with respect to the absorbance value of the cells before the treatments, which 
is showed as a dashed line in the graph; the cells in presence of the hPL (SF-hPL and hPL) have a significative 
increase in their viability (p<0.0001); for all the they, the cells cultivated in presence of the hPL released from the 
fibers (SF-hPL) had no significative difference (p>0.05) with those grown with hPL in the medium (hPL); b) and 
c) Confocal images of HDFa cells seeded onto the SF and SF-hPL fibrous mats at 5 days of culture. F-actin is 
stained with the Alexa-fluor phalloidin (green), while nuclei are stained with DAPI (blue). 
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Figure 7: hPL activity of dissolved hPL, lyophilized hPL and hPL released from SF-hPL matrices after the 
accelerated stability test. The activity of the hPL released from the fibers after 3 days of thermal treatment had 
statistically more activity than the lyophilized hPL (p<0.05) and dissolved hPL (p<0.0001).  
 
 
TABLES 
 
 
 
Table I: (a) Summary of the release kinetics of FITC-albumin from SF-alb and SF-alb-hPL samples reported in 
Figure 3. (b) FITC-albumin releasing rate from silk fibroin fibrous mats at different crystallinity. The rates derive 
from the graph in Figure 3.  
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SUPPLEMENTARY MATERIAL 
 
  
 
Figure S1: (a) Electrospinning set-up used to fabricate the different silk fibroin fibers mats. (b) Schematic of the 
water vapor treatment set-up used to increase the fibroin crystallinity.  
 
 
 
Figure S2: SEM images of SF-alb (a and b) and SF-alb-hPL (d and e) fibrous mats obtained via electrospinning. 
The fiber morphology is characterized before (a and d) and after (b and e) the water vapor treatment. Insets show 
the correspondent distribution of the fibers dimensions. Photo of the obtained electrospun SF-alb (c) and SF-alb-
hPL (d) fibrous mats. (g) SDS-page of a BSA standard and hPL at different concentration. 
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Figure S3: FITC-albumin released from electrospun mats in PBS buffer (left) and in PBS containing 0.25 
U/mgfibers of protease XIV (right). The percentages indicate the crystallinity of the electrospun mats used in the 
experiments. 
 
 
     
Figure S4: FITC-albumin released in PBS buffer from electrospun mats loaded with FITC-albumin (a) and 
loaded with both FITC-albumin and hPL (b). The percentages indicate the crystallinity of the electrospun mats 
used in the experiments. 
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Figure S5: The graph shows HDFa cell viability upon treatment with different concentrations of hPL. On the left 
confocal images depicting HDFa cells seeded on glass coverslips for (a) 1, (b) 3, and (c) 5 days; HDFa cells 
seeded on glass coverslips and treated with hPL-containing media for (d) 1, (e) 3, and (f) 5 days. F-actin is stained 
with the Alexa-fluor phalloidin (green), while nuclei are stained with DAPI (blue). 
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Figure S6: Confocal images depicting HDFa cells seeded on silk fibroin mats for (a) 1 and (b) 3 days; HDFa 
seeded on SF-hPL mats for 1 (c) and 3 (d) days; F-actin is stained with the Alexa-fluor phalloidin (green), while 
nuclei are stained with DAPI (blue). 
    
Figure S7: In a and d, confocal images of HDFa cells seeded on glass coverslips respectively without and with 
hPL. In b and c HDFa seeded respectively on film of silk fibroin and silk fibroin/PEO, respectively; in e and f 
HDFa, respectively on film of silk fibroin/hPL and silk fibroin/PEO/hPL, respectively. The images were acquired 
after 3 days of culture. F-actin is stained with the Alexa-fluor phalloidin (green), while nuclei are stained with 
DAPI (blue).  
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3. SERICIN, ALGINATE AND PLATELET LYSATE COMBINED 
IN A BIOMEMBRANE FOR THE TREATMENT OF SKIN 
ULCERS. 
 
ABSTRACT 
Chronic skin wounds with different etiophatology heavily compromise the patients' life quality and 
represent a high and constantly growing cost for National Health Services. Platelet derivatives (PL) 
has been used in clinical practice for reparative treatments of these pathologies, given their capacity 
to activate cell recruitment, proliferation, differentiation, as well as to regulate angiogenesis. We 
here report the development of a sericin/alginate sponge-like membrane as a new delivery system of 
PL.  
Sericin (SS), alginate (Alg) and PL were solubilized in distilled water and cast into freeze-dried 
molds. An in vitro test was performed to quantify the growth factor release from sponge/PL 
membrane by ELISA kit. The in vitro capability of SS and PL, contained in our membrane, to 
induce proliferation and protective effects against oxidative stress was performed on BMSCs and 
human fibroblast (hFB) with MTT assay. In vivo efficacy of sponge/PL was evaluated by skin 
mouse model. The lesions were treated with sponge membranes, with or without PL, and covered 
by Tegaderm™. The animals were sacrificed at different times (3, 7, 14 and 21 days and a 
histological investigation was performed.  
In vitro results indicated that the release of growth factors and the biodegradation of sponge 
membrane occurred within 48 hours, a time optimized to burst the healing process. The presence of 
SS contributes and support the effect of PL by controlling the release of growing factors. 
The proliferation effects and the protection against the oxidative stress of our membrane, monitored 
on BMSC cells and hFB, was prevalently due to the presence of PL.  
This in vivo analyses showed how Alg:SS:PL membrane led to a faster regeneration of the skin 
respect to the control one (Alg:SS). The inflammation phase occurred faster in treated lesion to 
evolve rapidly in the formation of granulation tissue and forming new collagen. These 
concatenation of events showed a non-complete resolution of the healing process in control lesions, 
but a burst of chronic inflammation probably induced by the presence of platelet derivatives as 
reported in several papers. 
In this context we have studied and characterized a biomembrane composed of sericin, alginate in 
combination with a powerful inductor of cell proliferation, PL, that lead to complete skin 
regeneration. The SS contribute and support the effect of PL by its controlling its release into the 
lesion. 
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INTRODUCTION  
Skin wound healing requires the recruitment and activity of different cell types, such as native 
immune response cells, endothelial progenitors, keratinocytes, and fibroblasts.  
Platelet derived products, such as platelet gel, PRP or PL, have been used in the clinical practice for 
various reparative treatments since 1986 [133] to promote or facilitate the wound healing process. 
Wound treated with PL gel recovered more quickly in all patients, leading to a reduction of hospital 
stay and of the related cost. No adverse reactions were observed and all patients treated with platelet 
gel reported a significant pain relief, thus bettering their quality of life [168]. A recent review 
highlighted the positive effects of platelet-rich fibrin (a platelet concentrate produced without the 
use of non-coagulating factors) on wound healing of various soft tissue defects in medicine and 
dentistry [169].  
Silk sericin (SS) is a globular and water-soluble protein with a molecular weight up to 200 kDa that, 
together with fibroin, constitutes the silk cocoon. In the past years, SS was considered a waste 
product of textile industry because, during the silk production, sericin is eliminated from the fibroin 
filaments by a degumming process.  
The protein component is made of 17 amino acids, even if there are some differences depending on 
the variety of cocoon [170]. Generally, it is composed by 78% of polar amino acids (especially 
serine and aspartic acid) and by 22 % of non-polar amino acids [171].  
The antioxidant flavonoids are able to protect cocoons from the oxidative stress and to inhibit the 
action of tyrosine. Ethanoic extracts of silk cocoons showed an antioxidant activity approximately 
double than that of vitamin E. The antioxidant activity of SS is due to its amino acid sequence, 
which allows to eliminate the free radicals and the reactive oxygen species (ROS) [172] and 
increases the antioxidant activity of enzymes, such as the superoxide dismutase and the glutathione 
peroxidase [171]. The large amount of hydroxyl groups contributes to this activity chelating trace 
elements such as iron, zinc and copper. Other amino acids, such as L-alanine and L-glycine showed 
cytoprotective properties on hepatocytes and kidney tubule cells [173]. 
It has been shown that treatment with SS inhibited apoptosis induced by UVB and the hydrogen 
peroxide formation, suggesting a role of SS in preventing mitochondrial damage [174].  
The SS has often been added to the culture media not only for its ability to protect cells from 
oxidative stresses, but also for its mitogen effects, which occur according to yet unidentified 
mechanisms and which differ depending on the considered cell line [171].  
Several studies reported that SS supports and enhances the cell growth of insect cells [175] and 
mammalian cells [171]. Sahu et al. [176] investigated the potential of sericin as growth supplement 
in serum-free culture medium on murine fibrosarcoma cell line.  
The mitogen effect of SS on mammalian cells allowed its use also in regenerative medicine, as it 
could sustain the proliferation of keratinocytes and fibroblasts during the skin wound healing 
process[177]. The local administration of a SS cream on a skin lesion in a murine model 
significantly improved healing, when compared to a physiological solution or a cream without 
sericin [178].  
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Composite hydrogels, based on poly (γ-glutamic acid) and SS were used as wound dressing. These 
hydrogels promoted in vivo the granulation and capillary formation, as they maintained a moist 
healing environment, protected the wound from bacterial infection, absorbed excess exudates and 
promoted the reconstruction of the damaged tissue [179]. 
SS was also employed for treatment of burn-wounds, to prevent infections and reduce scars [180]. 
The treatment of wounds should remove exudate, if present, in order to prevent infections. For this 
reason, to date, wounds are often treated with dressings based on alginate, which has excellent 
biocompatibility and ability to adsorb exudate [181]. Alginates are water-soluble linear 
polysaccharides which are the major component of marine brown algae.  They are widely used for 
tissue engineering because of their simplicity to create hydrogels in the presence of bivalent cations. 
In fact, alginate is constituted by two monomers: β-D-mannuronic acid (M) and α-L-glucuronic 
acid (G) linked by α1-4 binding. Due to their structure, G domains establish ionic bonds with 
divalent cations, such as calcium and magnesium, thus forming a hydrophilic gel [182]. High G 
alginates form much more rigid gels, while high M alginates form much softer and flexible 
hydrogels [183]. 
Moreover, alginate dressings do not have any side effects, even if, sometimes, a burning sensation 
could be experienced by the patient as result of the rapid movement of fluid from the soft tissue into 
the dressing matrix [183].  
The combination of PL, alginate and SS led to the bird of highly effective bioactive devices for the 
treatment of chronic skin defects.  
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MATERIALS AND METHODS 
 
Membrane fabrication 
The sericin was obtained from cocoons of Bombyx mori belonging to the Orgosolo strain. They 
were degummed in an autoclave at 120 °C for 1 hour [172]. The resulting sericin solution was 
allowed to cool to RT and then spray dried using Büchi Mini Spray Dryer B-290. The sericin 
powder obtained was stored at -18 °C until use. 
Alginate is a commercial product provided by Sigma (MO, USA). 
Sericin and alginate powders were solubilized in water. At this point, two types of membranes were 
produced: Treated membranes obtained by addition of Platelet Lysate (PL) to the aqueous solution 
of sericin/alginate and control membranes to which PL was not added. The composition of the 
different of membranes synthesized is showed in the table below. 
 
Type of membrane Alginate (%) Sericin (%) PL (%) Name 
Control 50 50 0 Alg:SS 
Control 100 0 0 Alg 
Treated 25 25 50 Alg:SS:PL 
Treated 50 0 50 Alg:PL 
 
 
The membranes were fabricated in two different formulations, microspheres and sponges. The 
obtained solution was placed into special moulds (wells of 24 multi-wells), frozen and lyophilized 
to obtain circular sponges. To obtain the microspheres, the solution was spray dried one more time 
after the addition of PL. 
With both membrane formulations s, we performed preliminary in vivo tests to determine which 
membrane was easy to handle. Preliminary results guided our experiments toward the use of sponge 
formulation according also to our interest to develop a patch for skin repair. 
 
Kinetic release of membranes 
Dosage of proteins and growth factors released by membranes was performed on the released 
product obtained from membranes. The membranes were allocated in transwells: 300 µL of 
physiological solution was placed on the bottom of the plate and 100 µL directly inside of transwell 
to allow the dissolution of membrane and release of protein content. 
Approximately 350 µL of the physiological solution were collected at 30 min, 2, 4, 24, 48, 96, 120 
and 144 hours and approximately 350 µL of fresh solution were added to each well after each 
collection..The harvested solution was aliquoted and stored at -20 °C for further analysis. 
The total protein content was determined with BCA (Pierce™ BCA Protein Assay Kit) assay in all 
samples. Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF-BB) 
and Transforming Growth Factor Beta (TGF-beta) were evaluated in all samples by ELISA assays 
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(Human PDGF-BB ELISA kit, RayBiotech Inc; Human VEGF ELISA kit, Invitrogen; Human 
TGF-beta 1 Duo set ELISA R&D Systems) according to the manufacturer’s instructions. All the 
measurements were performed on three different preparations. By these analyses we studied the 
kinetic release of different factors, determining the percentage of factors released respect to the 
quantity uploaded of platelet lysate. 
 
Fourier transform infrared (FTIR) spectroscopy 
Fourier transform infrared spectroscopy was performed on both bioactive membranes and single 
components (silk sericin, platelet lysate and sodium alginate). Samples were analyzed using a 
Spectrum One Perkin-Elmer spectrophotometer (Perkin Elmer, Wellesley, MA, USA) equipped 
with a MIRacleTM ATR device (Pike Technologies, Madison, WI, USA). The IR spectra in 
transmittance mode where obtained in the spectral region of 4000-650 cm-1, with a resolution of 4 
cm-1. Measurements were carried out at least in triplicate.  
 
Cell cultures 
Human bone marrow stromal cells (BMSC) were obtained by treating femoral heads of patients 
undergoing orthopaedic surgery for hip rupture, who have previously signed an informed consent. 
The bone marrow was washed 5 times with PBS 1X. The obtained liquid was centrifuged at 1500 
rpm for 10 minutes. The supernatant was discarded while the pellet was recovered and re-suspended 
in the appropriate volume of α-MEM (Lonza, Belgium) to obtain 50-100 nucleated cells per square 
in Burker's chamber. Counting was carried out using a nuclear dye (0.1% methyl violet in 0.1M 
citric acid). After counting, the cells were plated at a consonant density and allowed to adhere. Only 
BMSC adhere to the bottom of the plate and therefore they were selected by washing the plates with 
PBS 1X. The cells were cultivated in α-MEM supplemented with 10% FBS or 5% of PL, 100 
UI/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine. Once the cells reached 
confluence, they were detached using 0.05% trypsin-0.01% EDTA, counted and plated at a density 
of 7 x 104 cells per 6 cm Ø Petri dish for cellular expansion. 
 
Human fibroblast cells (hFB) were obtained from human skin fragment derived from discarded 
samples of patients undergoing reconstructive mastoplasty surgery, who have previously signed an 
informed consent. The skin was separated from the fat layer below. The extracted pieces were 
disinfected by immersion in 70% ethanol followed by two washes in sterile 1X PBS. To extract 
cells, the tissue fragments were transferred into a 10 cm Ø tissue culture dish using sterile scalpel 
avoiding the transfer of excess of PBS with the sample. The tissue was cut using two scalpels into 
~1 mm pieces that were transfered to the centre of a sterile 10 cm Ø Petri dish. A sterile slide was 
put over the tissue exercising a pressure over the skin fragments. Then,  α-MEM (Lonza, Belgium) 
supplemented with 10% FBS or 5% of platelet derivatives, 100 UI/mL penicillin, 100 µg/mL 
streptomycin and 2 mM L-glutamine was added. The fibroblasts start to exit the tissue fragments 
within 7 days. 
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Once the cells reached confluence, they were detached using 0.05% trypsin-0.01% EDTA, counted 
and plated at a density of 7 x 104 cells per 6 cm Ø Petri dish cellular expansion. 
 
Proliferation assay 
Cell viability was  assayed performed to test the biocompatibility of sericin alone or in combination 
with PL, since alginatehas been already reported in literature to be biocompatible [184]. Thiazolyl 
blue staining (MTT) was performed on BMSC and hFB grown in serum free medium or in medium 
containing SS PL or SS and PL in combination. BMSC and hFB at a density of 1 x103 cells per well 
were plated in a 96-well plate in 10% FBS. The day after, the cells were washed with PBS to 
remove the FBS and exposed to the different treatments. 
Cell proliferation was assayed 0, 24, 48 and 72 hours after treatment. At each time point, cells were 
incubated with MTT for 3 hours, then the MTT solution was removed and 100 µL of absolute 
ethanol was added per well to solubilize the formazan product. The reduction of MTT to formazan 
was quantified by reading the absorbance at 570 nm and 670 nm by spectrophotometry. 
All tested conditions are summarized in the table below: 
 
 
Condition Serum 
Free 
5% PL 1% 
Sericin 
1 √ - - 
2 - - √ 
3 - √ - 
4 - √ √ 
 
 
Oxidative stress induction and anti-oxidant assay 
BMSC and hFB were seeded as described above and grow on medium contained SF, PL or a 
combination of both. Oxidative stress was induced by treating the cells with 3 mM H2O2 for 24 h. 
The antioxidant capacity of sericin was evaluated by MTT assay as described above. 
The MTT reading was performed after 24, 48 and 72 hours after treatments. 
The treatments applied are summarized in the table below. 
 
Condition 5% PL 3 mM 
H2O2 
1% 
Sericin 
1 - √ - 
2 - √ √ 
3 √ √ - 
4 √ √ √ 
 
		 75	
In vivo analysis-mouse wound healing model 
In vivo tests were performed to determine the efficiency of our membranes. C57/BL6 wt mice were 
anesthetized with xylazine/ketamine. Once anesthetized, the mice were depilated on the dorsal 
surface with depilatory cream, so that mouse hair did not affect the evaluation of the wound closure. 
A full-thickness wound was performed with a circular 6mm punch.  An empty sponge (control) or a 
sponge loaded with PL (treated) was then applied over the wound Next, a transparent patch 
(Tegaderm) was applied over the lesions to protect the wound from any contact with external 
agents. After finishing the surgical procedure, mice were returned to their cages and kept under red 
light to compensate for the hypothermic effect of the anesthesia. Every two days the wounds were 
photographed. 
The mice treated with membranes containing sericin were euthanized with carbon dioxide  2,3,7,14 
and 21 days after surgery, while the mice treated with membrane containing only alginate were 
euthanized after 3,7 and 14 days. 
 
Histological analysis 
All harvested samples were fixed with 4% paraformaldehyde at RT for 24 hours and paraffin 
embedded for tissue sectioning. 5 µm thickness sections were prepared and stained by hematoxylin-
eosin and trichrome blue staining. The evaluation of different parameters was performed following 
guidelines provided from Abramov et al. [185] in collaboration with Prof.ssa Grillo and Dr. 
Mastracci of the Department of Pathological Anatomy of Ospedale Policlinico San martino 
(Genova). 
 
Statistical analysis 
All in vitro experiments were conducted in duplicate on different primary cell cultures. Statistical 
analyses were performed using the two-way ANOVA provided by the Graphpad Software 
(www.graphpad.com). All in vivo experiments were conducted in triplicate for the membranes of 
Alg:PL and seven time for Alg:SS:PL membranes at time 3-7 and 14 days, instead, was conducted 
in triplicate for 2 and 21 days. Statistical analyses were carry out using Mann-Whitney test to 
evaluate in the best possible way, the differences between treated and control lesions. 
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RESULTS 
 
Characterization of the sponges  
We performed a deep characterization of the biomembrane, evaluating the growth factors released 
in term of kinetic analysis and quantization of total content of proteins to determine the efficiency 
of this new typology of membrane. 
First, we compared the total protein content in both membranes based on Alg:PL and Alg:SS:PL. 
The histogram in figure 1 shows the release of the proteins for both membranes with the same trend 
but different protein content. The differences in term of total proteins released were attributed to the 
presence of sericin in one of the two sponges, that is a protein. 
Considering that the membranes were loaded with the same quantity of PL (50% w/w), 
standardized for the equal platelet count, we evaluate the release by the measurements of the 
principal growth factors contained in PL, PDGF-BB, VEGF and TGF-β,  as reported in literature 
[3] using ELISA tests. 
In the Figure 2 a, b and c  is showed the released product of VEGF, PDGF-BB and TGF-β 
respectively in both membranes. The statistical analysis demonstrated that VEGF is released in the 
similar way (not statistically significant), whereas the PDGF-BB and TGFb are released differently 
for both membranes (Fig. 2 b-c).  
 
Growth factors kinetic release from sponges 
To evaluate the kinetic release of the three principal growth factors released from both membranes, 
(Alg:SS:PL and Alg:PL), we performed the analysis as described in material and methods. The 
harvested samples were analysed for the total amount of PDGF-BB, VEGF and TGF-β respectively 
as represented in Figure 3 and reported each value in term of percentage, like the maximum 
capability of the sponge to release a specific growth factor. For each time point, we estimated the 
ability of the membranes to release the factors in term of percentage. 
PDGF-BB kinetic release showed statistical differences between the Alg:PL and Alg:SS:PL 
membranes during time (Fig. 3b). The same behaviour is registered for TGF-β (Fig. 3c), but not for 
VEGF (Fig. 3a). 
Considering the different curves of released PDGF-BB, VEGF and TGF-β, we underlined that in 
Alg:SS:PL membrane the PDGF-BB showed a burst in the first 4 hours to which follows a gradual 
release to reaches a plateau during next hours. Instead for the membrane composed of Alg:PL we 
observed a growing release during time and any burst was evident. 
 
FTIR analyses of single component and membranes  
FTIR spectrum of silk sericin (Figure 4a) showed a peak between 1800-1600 cm-1 and 
characteristics of the stretching vibration of C=O groups. Peaks at 3500-3000 cm-1 are associated 
with N-H stretching vibrations. At 1513 cm-1 it was possible to show an amide II absorption band; 
while C=O symmetry stretching was observed at about 1400 cm-1 (1397 cm-1). FTIR peaks of 
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lyophilized silk sericin considered for this study was similar to those obtained by other researchers 
[172,186,187]. 
Sodium alginate FTIR spectrum (Figure 4a) presented absorption bands around 1590 cm-1, 1402 
cm-1, and 1291 cm-1 that are correlated to stretching vibrations of asymmetric and symmetric bands 
of carboxylate anions. A not well resolute band at about 3400 cm-1 is characteristic of –OH 
stretching vibrations. Similar spectra, presenting the same characteristic absorption bands, were 
obtained by Khurana et al. [188] and Rao et al. [189]. 
FTIR analysis of PL (Figure 4a) showed the characteristics peaks of proteins, as reported by Barth 
[190]. The NH stretching vibration of amide A and B gives rise two to bands at 3277 and 3061 cm-
1, respectively. Absorption band at 1641 cm-1 is correlated to C=O stretching vibration of amide I, 
while peaks at 1540 and 1451 cm-1 are related to the amide II bending and stretching vibrations (NH 
and CN groups, respectively). Contributions of amide III-correlated NH bending vibration are 
visible in the 1400-1200 cm-1 region.  
After analysis of single components, FTRI was performed on alginate, sericin and platelet lysate-
based membrane (Figure 4 b) demonstrating the simultaneous presence of absorption bands related 
to OH stretching vibration of alginate chains and to NH stretching vibration of platelet lysate (3400-
3000 cm-1 region). In the region 1600-1100 cm-1 peaks are principally correlated to the amides of 
platelet lysate (1538, 1402, 1121 cm-1). An interaction between two components was observed by 
the shift of absorption bands of sodium alginate, from 1595 to 1590 cm-1, and of platelet lysate, 
from 1294 to 1305 cm-1. FTIR spectrum of Alg:SS:PL membrane was superimposable to the 
spectrum of control membrane (Alg:PL) though a peak at 1639 cm-1, attributable to the presence of 
sericin, was well-visible. Moreover, the addiction of silk sericin to bioactive membrane induced the 
interaction between functional groups of protein chains; in particular, it was possible to observe the 
presence of a well-defined peak at 1241 cm-1, not visible in platelet lysate and sericin spectra, 
owing to C-N stretching vibrations in the amide III linkage. 
 
Biocompatibility of the membranes 
To evaluate the biological efficiency of alginate and sericin based biomembranes we tested the 
capacity of cells to proliferate under the stimulation with sericin. In literature it has been already 
demonstrated that the alginate is inert in terms of biocompatibility [191], but it plays an important 
mechanical role [192,193] because it can form hydrogels simulating extracellular matrices of living 
tissues [191]. 
Sericin effect on a BMSC and hFB cells is evaluated in term of cell proliferation: as reported in the 
Figure 5 a, in BMSC the sericin alone sustained the vitality of the cells without statistically 
significant differences respect to the medium alone (SF). However, when sericin was in 
combination with PL, cell proliferation was significantly increased compared to SF condition at 
successive time points (p=0,0199 at 24 hours, p=0,0001 at 48 hours and p<0,0001 at 72 hours). 
Also in hFB (Figure 5 b), sericin alone maintained the cell vitality with statistically significant 
difference at all time points (p<0,0001) and when in combination with PL, cell proliferation is 
		78	
increased and the difference from SF condition is statistically significant on progressive time points 
(p=0,0245 at 24 hours, p<0,0001 at 48 hours and p<0,0001 at 72 hours). 
 
Protection against oxidative stress due to membrane 
In literature it has been reported that the SS plays a role in protection of cells against oxidative 
stress [172]. To support the choose of SS in our membranes, we performed experiments of 
oxidative stress on BMSC and hFB administering to the cells a dose of hydrogen peroxide (3mM) 
that previously has been demonstrated to be toxic. 
We noticed (Figure 6a and b) that the cells treated with only 1% of sericin, the same amount 
contained into the membrane, is not sufficient to protect cells from oxidative stress if compared 
with only hydrogen peroxide in the medium (p≥0.9999 for BMSC and hFB for all the time points 
examinated). Sericin is more efficient in combination with PL against H2O2 for BMSC cells and 
hFB (p=0,0044 for BMSC and p=0,0016 for hFB at 24 hours, p<0,0001 at 48 hours and p<0,0001 
at 72 hours for both types of cells). Considering that the PL showed a protective effect from H2O2 
when was supplemented alone in the medium, we suggest that the real contribution to this 
protective effect of the Alg:SS:PL membrane in both types of cells was due to the PL. 
 
Sponge effect in excisional wound healing mouse model 
To evaluate the effect of the membranes in vivo, we used excisional wound healing mouse model in 
C57/BL6 mice. A full-thickness skin lesions were created in the back of the animals and a 
membrane was applied. For each animal we applied two membranes: one without PL as control and 
one with PL as treatment. First, we performed the in vivo experiment using sponges composed of 
Alg:SS, Alg, Alg:PL and Alg:SS:PL to evaluate if there were differences among the different 
compositions.  
The in vivo results were obtained from histological analysis of the samples recovered from the 
animals at different time of implant (2,3,7,14 and 21 days).  
In Figure 7 different steps of the wound healing process is reported as histological images 
comparing the Alg:SS:PL and Alg:SS membranes.  Hematoxilin-eosin staining showed the closure 
of the lesion in the treatment (Alg:SS:PL) and control (Alg:SS) at 3 weeks, highlighting a more 
organized tissue similar to healthy skin of the mouse in the treatment. At 3 days the inflammation is 
evident but completely substituted from the granulation tissue at 1 week. The results of histological 
analysis were based not only on macroscopic investigation but also on the evaluation of the 
parameters providing from Abramov et al. [185]: 1) inflammation is considered as acute 
inflammation defined by presence of neutrophils and chronic inflammation by presence of plasma 
and monocytic cells; 2) granulation tissue as granulation tissue amount and as granulation tissue 
fibroblast maturation where the degree of maturation of the granulation tissue was determined by 
the shape of fibroblast and their alignment; 3) collagen deposition according to the amount of more 
or less mature collagen fibers; 4) reepithelization based on the degree of closure of the lesion and 5) 
neovascularization on the number of counted vessels. 
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Preliminary in vivo tests on three animals per group, demonstrated that the membranes containing 
Alg without SS didn’t show any different effect in the closure of the skin lesions respect to the the 
membranes containing SS (data not shown). 
In this respect we increased the animal number per group, comparing the Alg:SS and Alg:SS:PL 
membranes to focus the attention on the role of PL and SS. All evaluations were reported in the plot 
as difference between the treatment and control membranes. As reported in Figure 8 (a) acute 
inflammation was more evident in the control respect to the treatment after two days, whereas (b) 
the chronic inflammation was clearly more evident in the treatment. In the following times there is 
no statistically significant difference between the control and the treatment for both acute and 
chronic inflammation. At 21 days chronic inflammation appeared evident only in the control. 
The parameter concerning the granulation tissue is evaluated as (c) granulation tissue amount and 
(d) granulation tissue fibroblast maturation. All these parameters showed an increment in the 
treatment respect to the control after 3 days statistically significant respect to 7 days. (e) The 
collagen deposition was more evident in the treatment respect to the control and no statistically 
significant difference was at different time of implant. 
(f) The reepithelization occurred faster in treated wound showing no difference between treatment 
and control until 7 days. At 14 days an increment of the reepithelization in the treatment was 
evident. 
In term of neovascularization (g) any difference was noticed between the two lesions until 14 days 
where the control lesion showed a prevalence of vessels. This could be due to the delay in the 
wound healing process in the control animal in which, at the same time during the treatment, the 
reepithelization occurred.  
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DISCUSSION 
Autologous platelet-derived products, such as Platelet Rich Plasma gel, have been used in the 
clinical practice for various regenerative treatments [10–13].  
Many studies have been conducted to evaluate the effectiveness of PRP gel for the treatment of 
chronic and diabetic ulcers [2,194,195]. The PRP gel is derived from blood by the combination of 
PRP and a fibrin rich matrix extracted from plasma, which in presence of thrombin and calcium 
generates a growth factor enriched membrane [27,196,197]. Released growth factors activate a 
cascade of signals that lead to the tissue repair [197]. The platelets are widely recognized as having 
a critical role in primary hemostasis and thrombosis and experimental and clinical evidences 
identified these enucleated cells as relevant modulators of other physiopathological processes 
including inflammation and tissue regeneration. These phenomena are mediated through the release 
of growth factors, cytokines and extracellular matrix modulators that sequentially promote (i) 
revascularization of damaged tissue through the induction of migration, proliferation, differentiation 
and stabilization of endothelial cells in new blood vessels; (ii) restoration of damaged connective 
tissue through migration, proliferation and activation of fibroblasts; and (iii) proliferation and 
differentiation of mesenchymal stem cells into tissue-specific cell types. For these reasons, PRP 
derivatives are used in regenerative medicine for the treatment of several clinical conditions 
including ulcers, burns, muscle repair, bone diseases and tissue recovery following surgery. The 
benefits of PRP administration are associated with an economical advantage, taking into 
consideration that PRP administration does not require complex equipment or training for its 
execution [198]. For these reasons, many studies have been focused on the controlled release of 
platelet growth factors in the regenerative process studying the kinetic of release and the activated 
molecular mechanisms [71,72,199].  
In regenerative medicine the concept of biomaterial as scaffold to guide the cells into the site of 
tissue regeneration, it has also been used to control the release of the growth factors [200–202]. In 
this context we have considered a new tool to repair damaged tissue by the combination of platelet 
derivates and biomaterial based on Sericin, a silk protein. Silk sericin, a protein fiber, is derived 
from spider or some lepidoptera, from which they can be obtained fine fabrics. Primarily it can be 
collect from cocoons of silkworm of the Bombix mori specie.  
SS is a globular and water-soluble protein that has attracted much interest in the last years. In fact, 
this protein showed to effectively sustain the proliferation of different mammalian and insect cell 
lines and, thanks to its free-radical-scavenging activity, to protect them from the oxidative stress 
[203]. Due to its mitogen effect on mammalian cells, SS was also used for the improvement of the 
healing process. This protein has been found to have no immunogenicity and it is now utilized in 
biomedical applications [204]. An increasing number of studies have focused on the usefulness of 
sericin in biomedical applications because it has several biological activities, such as anti-oxidation, 
anti-bacterium, anti-coagulation and promotion of cell growth and differentiation [205–207]. In the 
field of regenerative medicine, owing to its biodegradability, easy availability, and hydrophilicity 
with many polar side groups, sericin is mostly copolymerized, crosslinked, or blended with other 
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polymers to form various scaffolds in order to help obtain improved properties for relevant 
biomedical applications [208–210] such as skin regeneration.  
 
During the wound healing process, to facilitate the tissue regeneration and prevent infections, 
wounds must be kept in a moist state, without excess of exudate. For this purpose, alginate, a 
natural and biocompatible polymer, was introduced as component of the membrane with SS and PL 
because of its absorbance and ability to form a gel [181]. In our work a membrane based on 
Alginate, sericin and platelet derivatives was developed for ulcer care and designed to control the 
release of platelet factors in the skin lesion. First, several combinations of three components were 
tested in term of release of growth factors (data not shown), choosing finally a ratio 25:25:50 of 
Alg:SS:PL. This composition was used to develop a device for skin regeneration. The growth factor 
release study was performed in the membranes containing PL monitoring PDGF-BB, VEGF and 
TGF-β factors; the protein content in the membrane composed of ALg:SS:PL was higher than the 
control membrane based only on Alg:PL due to the presence of sericin. The release kinetic studied 
by ELISA assay showed a different trend for the three factors monitored, VEGF and TGF-β  were 
released for the 50% in the first two hours, as an initial burst, from gel formation to follow a gradual 
release in the next 6 days until a plateau, for both typologies of membranes, with and without SS. 
PDGF-BB resulted to be released with the same trend of VEGF and TGF-β in the Alg:SS:PL 
membrane, whereas its release from Alg:PL membrane appeared more slowly and no initial burst 
occurred. In the hypothesis that this was related to a different affinity of growth factors to sericin an 
FTRI analysis was performed to understand the interaction among different components of the 
membrane. Fourier-transform infrared spectroscopy (FTIR) is a technique used to obtain an infrared 
spectrum of absorption or emission of a material allowing the study the interaction among the 
molecules. Thus, FTIR analysis showed that  the addiction of silk sericin to bioactive membrane 
induced the interaction between functional groups of protein chains; the comparison of absorption 
spectra of the components showed a in particular the presence of a new well-defined peak, not 
visible in platelet lysate and sericin spectra, owing to C-N stretching vibrations in the amide III 
linkage.  
Considering the role of the sericin in the tissue regeneration, the effect of SS and PL was evaluated 
in cell proliferation and in oxidative stress condition of mesenchymal stem cell derived from bone 
marrow and skin fibroblasts. The dose of SS and PL supplemented to the culture medium simulated 
the same amount and ratio in which they are mixed in the membrane. The sericin has no effect on 
cell proliferation even if it is not toxic to cells because it allowed them to grow better than in serum 
free condition. Sericin in combination with PL favored the proliferation, but much of this effect has 
been attributed to PL. This behavior was reproduced in BMSC and fibroblast cells. This result is in 
line with the data published from other authors in the ability of SS to maintain cell vitality 
[211,212]. Regarding the protection of SS against oxidative stress induced by H2O2, our 
experiments showed that sericin alone was not sufficient to protect the cell vitality. But SS in 
combination with PL guaranteed the cell vitality also in oxidative stress culture conditions. This 
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effect was ascribable to the PL that alone showed the same effect. The BMSC and fibroblast had the 
same behavior [172,213]. 
These findings lead us to consider a key role of the PL as a good inductor of cell proliferation and 
protector from oxidative stress condition and the SS a good modulator of its release. To be more 
sure of our hypothesis derived from in vitro experimental data, a wide study in vivo in mouse skin 
regeneration model was performed. Membranes based on Alg:SS:PL and Alg:SS were applied on 
the back of mouse where a critical skin lesion was created. The samples recovered at different time 
from the application on the cute were histologically analyzed. 
This analysis showed that Alg:SS:PL membrane led to a faster regeneration of the skin respect to 
the control one (Alg:SS). The inflammation phase occurred faster in treated lesion to evolve rapidly 
in the formation of granulation tissue and forming new collagen. This concatenation of events 
showed a non-complete resolution of the healing process in control lesions, but a burst of chronic 
inflammation in the treated wounds, probably induced by the presence of platelet derivatives as 
reported previously in several studies [32]. Also the reepithelization phase occurred in 14 days in 
treated lesion respect to the neovascularization that delayed in the control lesion. This is associated 
with the inflammation, collagen deposition, granulation tissue formation parameters that led to 
conclude that there is a faster resolution of the wound healing process in the treated lesion.  
In conclusion this work propose a handle membrane composed of biomaterial (alginate and sericin) 
that are biocompatible and have particular mechanical properties [171,184,214,215] in combination 
with a powerful inductor of cell proliferation, PL, that lead to complete skin regeneration. The SS 
contribute and support the effect of PL by its controlling its release into the lesion. 
 
 
This work is in preparation: 
Sericin, alginate and platelet lysate combined in a biomembrane for the treatment of skin 
ulcers.  
Nardini M., Perteghella S., Cancedda R., Torre M.L., Mastrogiacomo M.  
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FIGURES 
 
 
          
               
Figure 1: Proteins release during time from our membrane. There is not a statistical analysis because the two 
membrane cannot be compared in terms of protein because the presence of sericin in one of the two membranes. 
 
       
      
Figure 2: Release of the principal growth factors contained in PL from Alg:PL and Alg:SS:PL membranes 
overtime. No statistical differences were observed in released VEGF (a); the release of PDGF-BB was higher 
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form Alg:SS:PL membranes starting from 4 h until 96h (b); (c) TGF-β was higher released from Alg:SS:PL 
membranes starting from 2 h until the end of the experiment (144 hours).  * p<0.05, **<0.01, ***p<0,0001. 
      
 
 
Figure 3: The curves represent the kinetic of the release of three different factors expressed as percentage of the 
maximum release; VEGF (a) without statistical differences, PDGF-BB (b) with a statistical difference between the 
two membrane from 2 to 96 hours (p<0,0001) and TGF beta (c) with statistical difference from 2 to 48 hours 
(p<0,0001). 
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Figure 4: Fourier transform infrared (FTIR) spectroscopy was performed on both single components (silk sericin, 
PL and sodium alginate) (a) and bioactive membranes (b)  The IR spectra where obtained in the spectral region of 
4000-650 cm-1.  
 
 
		86	
         
 
 
Figure 5: The two graphs show the cells viability in presence of sericin. We perform the experiments with two 
different cell types BMSC (a) and hFB (b). * p<0.05, ** p<0.01 and *** p<0.0001.  
 
 
 
 
 
Figure 6: The two graphs show the cells viability after oxidative stress induced by H2O2 (3mM) and treatment 
with sericin. We perform the experiments with two different cell types BMSC (a) and hFB (b). * p<0.05, ** 
p<0.01 and *** p<0.0001.  
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Figure 7: Histological analysis of treated (Alg:SS:PL) and untreated (Alg:SS) lesions. Images were acquired at 5x 
magnification (5mm scale bar) and 20x magnification (1mm scale bar). The sections were cut at 5 µm thickness 
and stained with haematoxylin-eosin. 
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Figure 8: Statistical analyses of histological evaluations following the parameters provided by Abramov et al. 
[185]. 
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Pharm. Sci. 2016, 105, 1180–1187, doi:10.1016/j.xphs.2015.11.047. 
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LIST OF PUBLICATION AND OTHER SCIENTIFIC ACTIVITIES 
 
Publications 
• Platelet-rich plasma-based bioactive membrane as a new advanced wound care tool. 
Spanò R., Muraglia A., Todeschi M.R., Nardini M., Strada P., Cancedda R., Mastrogiacomo 
M. J. Tissue Eng Regen Med. 2016 Nov 13. doi: 10.1002/term.2357. 
• Culture medium supplements derived from human platelet and plasma: cell 
commitment and proliferation support. 
Muraglia M., Nguyen V.T., Nardini M., Mogni M, Coviello D., Strada P., Baldelli I., 
Formica M., Cancedda R., Mastrogiacomo M. Front. Bioeng. Biotechnol. doi: 
10.3389/fbioe.2017.00066 In publication 
• Electrospun silk fibroin fibers for storage and controlled proteins release. 
Pignatelli C., Perotto G., Nardini M., Mastrogiacomo M., Bayer S. I., Cancedda R. and 
Athanassiou A. Acta Biomater. Submitted 
• Sericin, alginate and platelet lysate combined in a biomembrane for the treatment of 
skin ulcers.  
Nardini M., Perteghella S., Cancedda R., Torre M.L., Mastrogiacomo M. In preparation 
• Role of C-MYC in the proliferation stage of mesenchymal stem cells cultured and 
selected by platelet derivatives  
Nardini M., Gentili C., Cancedda R., Castagnola P., Mastrogiacomo M. In preparation 
 
 
National and International meeting 
• Training Event “Il futuro terapeutico delle cellule stromali mesenchimali”, GISM; 
Fondazione Poliambulanza; IZLER October 20, 2017 Brescia (IT) 
• European Chapter Meeting of TERMIS 2017, TERMIS, June 26-30, 2017 Davos (CH) with 
the following poster: Platelet growth factor activated biomembrane as medical patch in skin 
regeneration 
• Advance in stem cells and regenerative medicine, EMBO Conference, May 23-26, 2017 
Heidelberg (DE) with the following poster: Platelet growth factor activated biomembrane as 
medical patch in skin regeneration 
• Scientific Meeting “Life science for a better future”, Associazione Italiana di Biologia e 
Genetica, May 11-13, 2017 Santa Margherita Ligure (IT) with the following oral 
presentation: Platelet growth factor activated biomembrane as a medical patch in skin 
regeneration 
• GISM Annual Meeting 2016, GISM; Fondazione Poliambulanza; IZLER October 20-21, 
2016 Brescia (IT) with the following poster: The c-Myc1 isoform is specifically induced by 
platelet lysate stimulation in mesenchymal stem cells. 
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• European Chapter Meeting of TERMIS 2016, TERMIS, June 28 July 1, 2016 Uppsala (SE) 
with the following poster: Smart platelet-rich-plasma based bioactive membrane as a new 
advanced wound care tool 
• Training Event “Corso base sulla sperimentazione animale per la realizzazione di procedure 
su animali in ottemperanza al D. LGS 26/2014”, Regione Liguria, November 11-12, 2015 
Genova (IT)  
• GISM Annual Meeting 2015, GISM; Fondazione Poliambulanza; IZLER October 8-9, 2015 
Brescia (IT) 
• Summer School on Biomaterials and Regenerative Medicine University of Trento July6-8 
2015 Riva del Garda (IT) 
• Stem Cells, Cancer, Immunology and Aging Fondazione Internazionale Menarini February 
12-14 2015 Genova (IT) 
 
Responsibilities 
Support work for the practical laboratory experiences relative to the following academic courses: 
• 2014/2015 Biologia Cellulare e dello sviluppo e Laboratorio di Colture Cellulari e di 
Biologia dello sviluppo, for the Bachelor’s degree in Biotechnology (32 hours) 
• 2015/2016 Biologia Cellulare e dello sviluppo e Laboratorio di Colture Cellulari e di 
Biologia dello sviluppo, for the Bachelor’s degree in Biotechnology (32 hours) 
• 2016/2017 Biologia Cellulare e dello sviluppo e Laboratorio di Colture Cellulari e di 
Biologia dello sviluppo, for the Bachelor’s degree in Biotechnology (32 hours) 
• 2017/2018 Biologia cellular II e Laboratorio, for Master degree in Farmaceutical and 
Medical Biotechnology (32 hours) 
 
Training activities 
• From 31.07.17 to 01.08.17 Visiting PhD Student at Institute of Nanotechnology-Laboratory 
for Soft and Living Matter- National Research council (CNR), Università la Sapienza Rome, 
Italy under the supervision of Dr. Cedola Alessia to acquire specific know how on the 
elaboration of imagines acquired with Synchrotron Radiation 
• From 14.07.16 to 18.07.16 Training during PhD course at ESRF- European Synchrotron 
Radiation Facility- Grenoble (F) under the supervision of Dr. Alberto Gravin to execution of 
experiments. 
 
Other activities 
• Co-author of a patent regarding the validation of platelet derivatives associated to 
biomembranes useful as therapeutic agents (University of Genoa Partner) registered on 
February 21 2017 with n° 102017000117327. 
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• Member of Participant Unit in a Phase II randomized clinical trial (PATCH II) for the use 
of allogeneic platelet rich plasma for the treatment of skin chronic ulcers in diabetic patient 
as monocentric study approved from ethical committee of Ospedale Policlinico San Martino  
Study Chairman: 
Domenico Palombo, Chirurgia vascolare, IRCCS AOU San Martino-IST, Genova, Italia 
Ranieri Cancedda, Medicina Rigenerativa, DIMES Università di Genova, Italy 
Participant Units:  
Maddalena Mastrogiacomo, Marta Nardini, Medicina Rigenerativa DIMES Università di 
Genova  
Alessandro Poggi; Unità di Biologia Molecolare e angiogenesi, IRCCS Ospedale San 
Martino –IST 
Aurora Parodi, Cozzani Emanuele; Clinica Dermatologica Università di Genova- , IRCCS 
Ospedale San Martino –IST 
Pierluigi Santi, Baldelli Ilaria; Chirurgia plastica e ricostruttiva Università di Genova, 
IRCCS Ospedale San Martino –IST 
Paolo Bruzzi, Epidemiologia Clinica, IRCCS AOU San Martino-IST, Genoa, Italy 
Ferdinando Felli, Matteo Formica, Clinica Ortopedica, IRCCS AOU San Martino-IST, 
Genova, Italia  
The study started in June 2017 and is still going. 
 
 
 
 
 
